The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Acade...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Allergy (Copenhagen) Ročník 77; číslo 3; s. 734 - 766
Hlavní autoři: Zuberbier, Torsten, Abdul Latiff, Amir Hamzah, Abuzakouk, Mohamed, Aquilina, Susan, Asero, Riccardo, Baker, Diane, Ballmer‐Weber, Barbara, Bangert, Christine, Ben‐Shoshan, Moshe, Bernstein, Jonathan A., Bindslev‐Jensen, Carsten, Brockow, Knut, Brzoza, Zenon, Chong Neto, Herberto Jose, Church, Martin K., Criado, Paulo R., Danilycheva, Inna V., Dressler, Corinna, Ensina, Luis Felipe, Fonacier, Luz, Gaskins, Matthew, Gáspár, Krisztian, Gelincik, Aslı, Giménez‐Arnau, Ana, Godse, Kiran, Gonçalo, Margarida, Grattan, Clive, Grosber, Martine, Hamelmann, Eckard, Hébert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Kessel, Aharon, Kocatürk, Emek, Kulthanan, Kanokvalai, Larenas‐Linnemann, Désirée, Lauerma, Antti, Leslie, Tabi A., Magerl, Markus, Makris, Michael, Meshkova, Raisa Y., Metz, Martin, Micallef, Daniel, Mortz, Charlotte G., Nast, Alexander, Oude‐Elberink, Hanneke, Pawankar, Ruby, Pigatto, Paolo D., Ratti Sisa, Hector, Rojo Gutiérrez, María Isabel, Saini, Sarbjit S., Schmid‐Grendelmeier, Peter, Sekerel, Bulent E., Siebenhaar, Frank, Siiskonen, Hanna, Soria, Angele, Staubach‐Renz, Petra, Stingeni, Luca, Sussman, Gordon, Szegedi, Andrea, Thomsen, Simon Francis, Vadasz, Zahava, Vestergaard, Christian, Wedi, Bettina, Zhao, Zuotao, Maurer, Marcus
Médium: Journal Article
Jazyk:angličtina
Vydáno: Denmark Blackwell Publishing Ltd 01.03.2022
Wiley
Témata:
Allergies
Angioedema
Angioedema - diagnosis
Angioedema - etiology
Angioedema - therapy
Asthma
Chronic Disease
consensus
Dermatology
Edema
evidence‐based
hives
Humans
Immunology
itch
Life Sciences
mast cell
Medical diagnosis
Prevalence
Quality of Life
Urticaria
Urticaria - diagnosis
Urticaria - epidemiology
Urticaria - etiology
wheal
consensus
angioedema
itch
wheal
urticaria
hives
mast cell
evidence-based
ISSN:0105-4538, 1398-9995, 1398-9995
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.
AbstractList This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
Author Bindslev‐Jensen, Carsten
Makris, Michael
Magerl, Markus
Schmid‐Grendelmeier, Peter
Kocatürk, Emek
Staubach‐Renz, Petra
Hide, Michihiro
Kulthanan, Kanokvalai
Meshkova, Raisa Y.
Zhao, Zuotao
Gelincik, Aslı
Wedi, Bettina
Sekerel, Bulent E.
Giménez‐Arnau, Ana
Pigatto, Paolo D.
Larenas‐Linnemann, Désirée
Oude‐Elberink, Hanneke
Dressler, Corinna
Kaplan, Allen
Siiskonen, Hanna
Grattan, Clive
Szegedi, Andrea
Asero, Riccardo
Ballmer‐Weber, Barbara
Gonçalo, Margarida
Soria, Angele
Hébert, Jacques
Vestergaard, Christian
Metz, Martin
Maurer, Marcus
Bernstein, Jonathan A.
Abuzakouk, Mohamed
Church, Martin K.
Kapp, Alexander
Pawankar, Ruby
Siebenhaar, Frank
Ensina, Luis Felipe
Godse, Kiran
Abdul Latiff, Amir Hamzah
Mortz, Charlotte G.
Ratti Sisa, Hector
Brockow, Knut
Kessel, Aharon
Gáspár, Krisztian
Brzoza, Zenon
Criado, Paulo R.
Stingeni, Luca
Leslie, Tabi A.
Lauerma, Antti
Nast, Alexander
Zuberbier, Torsten
Bangert, Christine
Thomsen, Simon Francis
Saini, Sarbjit S.
Vadasz, Zahava
Micallef, Daniel
Baker, Diane
Chong Neto, Herberto Jose
Fonacier, Luz
Gaski
Author_xml – sequence: 1
  givenname: Torsten
  orcidid: 0000-0002-1466-8875
  surname: Zuberbier
  fullname: Zuberbier, Torsten
  email: torsten.zuberbier@charite.de
  organization: Humboldt‐Universität zu Berlin, and Berlin Institute of Health
– sequence: 2
  givenname: Amir Hamzah
  orcidid: 0000-0002-6304-0494
  surname: Abdul Latiff
  fullname: Abdul Latiff, Amir Hamzah
  organization: Pantai Hospital Kuala Lumpur
– sequence: 3
  givenname: Mohamed
  surname: Abuzakouk
  fullname: Abuzakouk, Mohamed
  organization: Cleveland Clinic Abu Dhabi
– sequence: 4
  givenname: Susan
  surname: Aquilina
  fullname: Aquilina, Susan
  organization: Mater Dei Hospital
– sequence: 5
  givenname: Riccardo
  orcidid: 0000-0002-8277-1700
  surname: Asero
  fullname: Asero, Riccardo
  organization: Clinica San Carlo
– sequence: 6
  givenname: Diane
  surname: Baker
  fullname: Baker, Diane
  organization: Asthma and Dermatology
– sequence: 7
  givenname: Barbara
  surname: Ballmer‐Weber
  fullname: Ballmer‐Weber, Barbara
  organization: University Hospital Zurich
– sequence: 8
  givenname: Christine
  orcidid: 0000-0003-3392-6590
  surname: Bangert
  fullname: Bangert, Christine
  organization: Medical University of Vienna
– sequence: 9
  givenname: Moshe
  surname: Ben‐Shoshan
  fullname: Ben‐Shoshan, Moshe
  organization: McGill University
– sequence: 10
  givenname: Jonathan A.
  orcidid: 0000-0002-3476-1196
  surname: Bernstein
  fullname: Bernstein, Jonathan A.
  organization: University of Cincinnati Physicians Immunology Research Center
– sequence: 11
  givenname: Carsten
  orcidid: 0000-0002-8940-038X
  surname: Bindslev‐Jensen
  fullname: Bindslev‐Jensen, Carsten
  organization: Odense University Hospital and University of Southern Denmark
– sequence: 12
  givenname: Knut
  orcidid: 0000-0002-2775-3681
  surname: Brockow
  fullname: Brockow, Knut
  organization: Technical University Munich
– sequence: 13
  givenname: Zenon
  orcidid: 0000-0002-1230-7013
  surname: Brzoza
  fullname: Brzoza, Zenon
  organization: University of Opole
– sequence: 14
  givenname: Herberto Jose
  surname: Chong Neto
  fullname: Chong Neto, Herberto Jose
  organization: Federal University of Paraná
– sequence: 15
  givenname: Martin K.
  surname: Church
  fullname: Church, Martin K.
  organization: University of Southampton
– sequence: 16
  givenname: Paulo R.
  orcidid: 0000-0001-9785-6099
  surname: Criado
  fullname: Criado, Paulo R.
  organization: Alergoskin (UCARE)
– sequence: 17
  givenname: Inna V.
  surname: Danilycheva
  fullname: Danilycheva, Inna V.
  organization: National Research Center‐Institute of Immunology Federal Medical‐Biological Agency of Russia
– sequence: 18
  givenname: Corinna
  orcidid: 0000-0001-7075-2062
  surname: Dressler
  fullname: Dressler, Corinna
  organization: Humboldt‐Universität zu Berlin, and Berlin Institute of Health
– sequence: 19
  givenname: Luis Felipe
  surname: Ensina
  fullname: Ensina, Luis Felipe
  organization: Federal University of São Paulo
– sequence: 20
  givenname: Luz
  surname: Fonacier
  fullname: Fonacier, Luz
  organization: New York University Long Island School of Medicine
– sequence: 21
  givenname: Matthew
  orcidid: 0000-0001-6436-2703
  surname: Gaskins
  fullname: Gaskins, Matthew
  organization: Humboldt‐Universität zu Berlin, and Berlin Institute of Health
– sequence: 22
  givenname: Krisztian
  surname: Gáspár
  fullname: Gáspár, Krisztian
  organization: University of Debrecen
– sequence: 23
  givenname: Aslı
  orcidid: 0000-0002-3524-9952
  surname: Gelincik
  fullname: Gelincik, Aslı
  organization: Istanbul University
– sequence: 24
  givenname: Ana
  surname: Giménez‐Arnau
  fullname: Giménez‐Arnau, Ana
  organization: Universitat Autònoma y Universitat Pompeu Fabra
– sequence: 25
  givenname: Kiran
  surname: Godse
  fullname: Godse, Kiran
  organization: Navi Mumbai
– sequence: 26
  givenname: Margarida
  orcidid: 0000-0001-6842-1360
  surname: Gonçalo
  fullname: Gonçalo, Margarida
  organization: University of Coimbra
– sequence: 27
  givenname: Clive
  surname: Grattan
  fullname: Grattan, Clive
  organization: St John’s Institute of Dermatology
– sequence: 28
  givenname: Martine
  surname: Grosber
  fullname: Grosber, Martine
  organization: Vrije Universiteit Brussel (VUB)
– sequence: 29
  givenname: Eckard
  orcidid: 0000-0002-2996-8248
  surname: Hamelmann
  fullname: Hamelmann, Eckard
  organization: University Bielefeld
– sequence: 30
  givenname: Jacques
  surname: Hébert
  fullname: Hébert, Jacques
  organization: Centre Hospitalier Université Laval/Centre Hospitalier Universitaire de Québec
– sequence: 31
  givenname: Michihiro
  orcidid: 0000-0002-1569-6034
  surname: Hide
  fullname: Hide, Michihiro
  organization: Hiroshima Citizens Hospital
– sequence: 32
  givenname: Allen
  orcidid: 0000-0002-6566-4743
  surname: Kaplan
  fullname: Kaplan, Allen
  organization: Medical University of South Carolina
– sequence: 33
  givenname: Alexander
  surname: Kapp
  fullname: Kapp, Alexander
  organization: Hannover Medical School (MHH)
– sequence: 34
  givenname: Aharon
  surname: Kessel
  fullname: Kessel, Aharon
  organization: Technion
– sequence: 35
  givenname: Emek
  surname: Kocatürk
  fullname: Kocatürk, Emek
  organization: Koç University School of Medicine
– sequence: 36
  givenname: Kanokvalai
  surname: Kulthanan
  fullname: Kulthanan, Kanokvalai
  organization: Mahidol University
– sequence: 37
  givenname: Désirée
  orcidid: 0000-0002-5713-5331
  surname: Larenas‐Linnemann
  fullname: Larenas‐Linnemann, Désirée
  organization: Hospital Médica Sur
– sequence: 38
  givenname: Antti
  surname: Lauerma
  fullname: Lauerma, Antti
  organization: University of Helsinki and Helsinki University Hospital
– sequence: 39
  givenname: Tabi A.
  surname: Leslie
  fullname: Leslie, Tabi A.
  organization: Royal Free Hospital
– sequence: 40
  givenname: Markus
  surname: Magerl
  fullname: Magerl, Markus
  organization: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology
– sequence: 41
  givenname: Michael
  surname: Makris
  fullname: Makris, Michael
  organization: University General Hospital "Attikon"
– sequence: 42
  givenname: Raisa Y.
  surname: Meshkova
  fullname: Meshkova, Raisa Y.
  organization: Smolensk State Medical University
– sequence: 43
  givenname: Martin
  orcidid: 0000-0002-4070-9976
  surname: Metz
  fullname: Metz, Martin
  organization: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology
– sequence: 44
  givenname: Daniel
  surname: Micallef
  fullname: Micallef, Daniel
  organization: Mater Dei Hospital
– sequence: 45
  givenname: Charlotte G.
  orcidid: 0000-0001-8710-0829
  surname: Mortz
  fullname: Mortz, Charlotte G.
  organization: Odense University Hospital and University of Southern Denmark
– sequence: 46
  givenname: Alexander
  orcidid: 0000-0003-3504-2203
  surname: Nast
  fullname: Nast, Alexander
  organization: Humboldt‐Universität zu Berlin, and Berlin Institute of Health
– sequence: 47
  givenname: Hanneke
  surname: Oude‐Elberink
  fullname: Oude‐Elberink, Hanneke
  organization: University of Groningen
– sequence: 48
  givenname: Ruby
  orcidid: 0000-0002-3091-7237
  surname: Pawankar
  fullname: Pawankar, Ruby
  organization: Nippon Medical School
– sequence: 49
  givenname: Paolo D.
  orcidid: 0000-0001-6599-9538
  surname: Pigatto
  fullname: Pigatto, Paolo D.
  organization: University of Milan
– sequence: 50
  givenname: Hector
  orcidid: 0000-0001-7852-3854
  surname: Ratti Sisa
  fullname: Ratti Sisa, Hector
  organization: Hospital de Clínicas de la Facultad de Ciencias Médicas‐Universidad Nacional de Asunción
– sequence: 51
  givenname: María Isabel
  surname: Rojo Gutiérrez
  fullname: Rojo Gutiérrez, María Isabel
  organization: Hospital Juárez de México
– sequence: 52
  givenname: Sarbjit S.
  surname: Saini
  fullname: Saini, Sarbjit S.
  organization: Johns Hopkins Asthma and Allergy Center
– sequence: 53
  givenname: Peter
  orcidid: 0000-0003-3215-3370
  surname: Schmid‐Grendelmeier
  fullname: Schmid‐Grendelmeier, Peter
  organization: University Hospital of Zurich
– sequence: 54
  givenname: Bulent E.
  orcidid: 0000-0001-7402-6850
  surname: Sekerel
  fullname: Sekerel, Bulent E.
  organization: Hacettepe University Faculty of Medicine
– sequence: 55
  givenname: Frank
  orcidid: 0000-0003-4532-1644
  surname: Siebenhaar
  fullname: Siebenhaar, Frank
  organization: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology
– sequence: 56
  givenname: Hanna
  surname: Siiskonen
  fullname: Siiskonen, Hanna
  organization: Kuopio University Hospital
– sequence: 57
  givenname: Angele
  orcidid: 0000-0002-8726-6658
  surname: Soria
  fullname: Soria, Angele
  organization: APHP Sorbonne University and Cimi‐Paris Inserm 1135
– sequence: 58
  givenname: Petra
  surname: Staubach‐Renz
  fullname: Staubach‐Renz, Petra
  organization: University Medical Center Mainz
– sequence: 59
  givenname: Luca
  orcidid: 0000-0001-7919-8141
  surname: Stingeni
  fullname: Stingeni, Luca
  organization: University of Perugia
– sequence: 60
  givenname: Gordon
  orcidid: 0000-0002-2202-2513
  surname: Sussman
  fullname: Sussman, Gordon
  organization: St. Michael's Hospital and University of Toronto
– sequence: 61
  givenname: Andrea
  surname: Szegedi
  fullname: Szegedi, Andrea
  organization: University of Debrecen
– sequence: 62
  givenname: Simon Francis
  surname: Thomsen
  fullname: Thomsen, Simon Francis
  organization: University of Copenhagen
– sequence: 63
  givenname: Zahava
  orcidid: 0000-0003-2899-5508
  surname: Vadasz
  fullname: Vadasz, Zahava
  organization: Technion
– sequence: 64
  givenname: Christian
  surname: Vestergaard
  fullname: Vestergaard, Christian
  organization: Aarhus University Hospital
– sequence: 65
  givenname: Bettina
  orcidid: 0000-0002-9868-6308
  surname: Wedi
  fullname: Wedi, Bettina
  organization: Hannover Medical School
– sequence: 66
  givenname: Zuotao
  orcidid: 0000-0002-9595-6050
  surname: Zhao
  fullname: Zhao, Zuotao
  organization: Peking University First Hospital
– sequence: 67
  givenname: Marcus
  orcidid: 0000-0002-4121-481X
  surname: Maurer
  fullname: Maurer, Marcus
  organization: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34536239$$D View this record in MEDLINE/PubMed
https://hal.science/hal-03982425$$DView record in HAL
BookMark eNp1kc1u1DAUhS1URKeFBS-AIrEBqWn8E2fGy2gYppUiYFHWlhPfTF05drGTor4Bz8Mj8GR4mmmREHhj-fq759rnnKAj5x0g9Jrgc5JWoaw9JxwL_AwtCBOrXAjBj9ACE8zzkrPVMTqJ8QZjvKQCv0DHLBUrysQC_bi6hsy4EYJTo_FO2WxT1-vLYlv_-tlsPhWbKfjtZD5AGIr6S72_y3aT0WCNg6z3IRuTgobeOLMXOMs6q2I0venUfNZG7ZyPJp5lyulsUE7tYAA3Zr7PpjAmMBj1Ej3vlY3w6rCfoq8fN1fri7z5vL1c103elZTifNkvMVFVSzXmwLTmQugKr9RKlG3HhFYVAd1SCm2v2lJ30LagebIA-q5dcs1O0ftZ91pZeRvMoMK99MrIi7qR-xpOBtKS8juS2Hczexv8twniKAcTO7BWOfBTlJQvSyYEITyhb_9Cb_yUPLWJqhgjmKXXJ-rNgZraAfTT_Mc8ElDMQBd8jAF62ZnxwccxKGMlwXKfuEyJy4fE__znqeNR9F_sQf27sXD_f1DWTTN3_Abz47oh
CitedBy_id crossref_primary_10_53126_MEB43635
crossref_primary_10_1016_j_jaci_2023_08_033
crossref_primary_10_1016_j_jaip_2022_11_016
crossref_primary_10_36290_csf_2024_002
crossref_primary_10_1111_pai_14236
crossref_primary_10_1016_j_jaci_2023_08_038
crossref_primary_10_3390_biomedicines11041096
crossref_primary_10_1080_1744666X_2023_2209319
crossref_primary_10_1111_all_15850
crossref_primary_10_1007_s13555_024_01319_5
crossref_primary_10_1111_all_15855
crossref_primary_10_1111_all_15854
crossref_primary_10_3389_fmed_2022_1048480
crossref_primary_10_1016_j_ad_2024_04_012
crossref_primary_10_1111_pai_70053
crossref_primary_10_1111_pai_70174
crossref_primary_10_2340_actadv_v104_18399
crossref_primary_10_1007_s00105_024_05320_z
crossref_primary_10_30569_adiyamansaglik_1294989
crossref_primary_10_7759_cureus_29662
crossref_primary_10_1016_j_jaip_2023_05_039
crossref_primary_10_1080_1744666X_2025_2538897
crossref_primary_10_53126_MEB41561
crossref_primary_10_3389_fimmu_2022_1056838
crossref_primary_10_3389_fimmu_2023_1192284
crossref_primary_10_1016_j_annder_2025_103425
crossref_primary_10_1016_j_jaip_2022_12_041
crossref_primary_10_1016_j_jaci_2025_04_004
crossref_primary_10_7189_jogh_14_04095
crossref_primary_10_1111_bjd_20892
crossref_primary_10_1016_j_jaip_2022_11_006
crossref_primary_10_1016_j_jaci_2023_08_020
crossref_primary_10_1016_j_jaip_2023_05_031
crossref_primary_10_53126_MEB43629
crossref_primary_10_1016_j_ad_2023_02_015
crossref_primary_10_1001_jama_2024_15568
crossref_primary_10_1016_j_jaip_2023_05_033
crossref_primary_10_1155_2024_8202476
crossref_primary_10_1016_j_jaci_2024_11_039
crossref_primary_10_1016_j_jaip_2025_08_018
crossref_primary_10_4168_aair_2023_15_5_695
crossref_primary_10_7759_cureus_40006
crossref_primary_10_1016_j_jaci_2024_11_036
crossref_primary_10_1159_000533394
crossref_primary_10_3390_jcm12020688
crossref_primary_10_1007_s11655_023_3741_x
crossref_primary_10_1016_j_abd_2022_06_003
crossref_primary_10_1177_12034754251316300
crossref_primary_10_1016_j_jaci_2023_07_019
crossref_primary_10_1111_pai_70038
crossref_primary_10_1007_s12016_025_09036_3
crossref_primary_10_1016_j_jaad_2023_02_062
crossref_primary_10_1097_ACI_0000000000001016
crossref_primary_10_3390_biomedicines10061260
crossref_primary_10_3389_fimmu_2022_1054445
crossref_primary_10_36290_ped_2023_097
crossref_primary_10_2500_aap_2025_46_250031
crossref_primary_10_2500_aap_2023_44_220101
crossref_primary_10_1016_j_waojou_2022_100719
crossref_primary_10_3238_arztebl_m2025_0122
crossref_primary_10_1007_s11882_025_01215_8
crossref_primary_10_1016_j_jaip_2023_05_019
crossref_primary_10_1016_j_jaip_2022_12_029
crossref_primary_10_3389_fimmu_2022_850993
crossref_primary_10_1007_s13555_025_01348_8
crossref_primary_10_1038_s41573_023_00750_1
crossref_primary_10_1136_bmjopen_2024_084987
crossref_primary_10_1016_j_med_2025_04_004
crossref_primary_10_3390_v15071585
crossref_primary_10_1186_s10194_024_01910_3
crossref_primary_10_1111_srt_13906
crossref_primary_10_1159_000538903
crossref_primary_10_1186_s40359_023_01284_2
crossref_primary_10_1016_j_jaip_2023_06_027
crossref_primary_10_3390_sports13070215
crossref_primary_10_1016_j_allmed_2025_100049
crossref_primary_10_1111_pai_70132
crossref_primary_10_1016_j_allmed_2025_100048
crossref_primary_10_1038_s43856_024_00656_y
crossref_primary_10_1016_j_cjac_2025_100512
crossref_primary_10_1016_j_reval_2023_103617
crossref_primary_10_7326_ANNALS_24_02701
crossref_primary_10_1016_j_anai_2024_01_003
crossref_primary_10_1111_ced_15316
crossref_primary_10_3390_ijms252413709
crossref_primary_10_1002_jvc2_324
crossref_primary_10_1111_ddg_15034_g
crossref_primary_10_15557_PiMR_2024_0042
crossref_primary_10_1016_j_ad_2025_05_004
crossref_primary_10_1016_j_jaci_2024_03_024
crossref_primary_10_1371_journal_pmed_1004390
crossref_primary_10_3390_jcm12237482
crossref_primary_10_1016_j_anai_2024_06_003
crossref_primary_10_1001_jamadermatol_2024_2863
crossref_primary_10_12956_tchd_1587146
crossref_primary_10_1111_all_15304
crossref_primary_10_1016_j_jaip_2023_06_034
crossref_primary_10_1016_j_jaip_2023_06_033
crossref_primary_10_1159_000543021
crossref_primary_10_1016_j_jaip_2023_06_030
crossref_primary_10_1097_ACI_0000000000001047
crossref_primary_10_3389_fimmu_2024_1413233
crossref_primary_10_1007_s40261_025_01480_5
crossref_primary_10_1016_j_cyto_2024_156814
crossref_primary_10_3390_antiox14050555
crossref_primary_10_3389_fimmu_2022_883692
crossref_primary_10_1080_13543784_2023_2277385
crossref_primary_10_36469_001c_117589
crossref_primary_10_1007_s11882_025_01202_z
crossref_primary_10_4168_aair_2023_15_1_1
crossref_primary_10_25259_IJDVL_523_2024
crossref_primary_10_1111_exd_14785
crossref_primary_10_1111_all_15310
crossref_primary_10_1186_s13223_023_00771_w
crossref_primary_10_1159_000532021
crossref_primary_10_1016_j_jacig_2023_100159
crossref_primary_10_1007_s40521_023_00333_w
crossref_primary_10_1097_MD_0000000000044538
crossref_primary_10_2500_aap_2023_44_230044
crossref_primary_10_3390_healthcare10122579
crossref_primary_10_1007_s40521_024_00375_8
crossref_primary_10_3389_fimmu_2022_1053558
crossref_primary_10_1056_NEJMc2504726
crossref_primary_10_1186_s13223_024_00934_3
crossref_primary_10_1016_j_ad_2025_05_022
crossref_primary_10_1111_ddg_14932_g
crossref_primary_10_3389_fimmu_2024_1279976
crossref_primary_10_1007_s00011_024_01869_6
crossref_primary_10_1016_j_jaip_2022_09_018
crossref_primary_10_1186_s41687_024_00830_9
crossref_primary_10_1016_j_jaip_2024_08_021
crossref_primary_10_2500_aap_2023_44_230051
crossref_primary_10_3389_fcimb_2022_1094737
crossref_primary_10_1186_s12889_025_23321_y
crossref_primary_10_1136_bcr_2024_260364
crossref_primary_10_1007_s40629_023_00272_7
crossref_primary_10_1016_j_jaci_2025_05_019
crossref_primary_10_1016_j_wjam_2025_02_001
crossref_primary_10_1111_jdv_18387
crossref_primary_10_1007_s00403_023_02564_y
crossref_primary_10_1111_cea_70014
crossref_primary_10_1016_j_abd_2025_501198
crossref_primary_10_1002_clt2_12305
crossref_primary_10_3389_fimmu_2025_1584771
crossref_primary_10_1016_j_jaci_2022_04_010
crossref_primary_10_1186_s13052_022_01395_3
crossref_primary_10_1016_j_waojou_2023_100843
crossref_primary_10_1016_j_jaci_2023_10_007
crossref_primary_10_2147_JIR_S455489
crossref_primary_10_7759_cureus_61453
crossref_primary_10_1097_ACI_0000000000001079
crossref_primary_10_1111_jdv_19485
crossref_primary_10_1097_ACI_0000000000001095
crossref_primary_10_1111_jdv_18497
crossref_primary_10_1016_j_jaip_2025_07_021
crossref_primary_10_1097_ACI_0000000000001093
crossref_primary_10_1093_ced_llae319
crossref_primary_10_1111_dth_15887
crossref_primary_10_3389_fmicb_2022_1083432
crossref_primary_10_1016_j_jaci_2022_12_809
crossref_primary_10_3389_fimmu_2024_1441478
crossref_primary_10_1097_HM9_0000000000000145
crossref_primary_10_1111_cea_14538
crossref_primary_10_1111_cea_14531
crossref_primary_10_1097_MD_0000000000040603
crossref_primary_10_2147_CCID_S470160
crossref_primary_10_1016_j_jaip_2024_05_013
crossref_primary_10_1007_s00060_024_9157_1
crossref_primary_10_1016_j_jaip_2025_07_025
crossref_primary_10_1016_j_jaip_2024_05_011
crossref_primary_10_1016_j_jaci_2023_03_034
crossref_primary_10_1136_bmjopen_2024_091425
crossref_primary_10_1111_jdv_20204
crossref_primary_10_1016_j_waojou_2024_100905
crossref_primary_10_4103_ejdv_ejdv_84_24
crossref_primary_10_1002_clt2_12204
crossref_primary_10_1016_j_jaci_2025_06_004
crossref_primary_10_1016_j_jaip_2022_02_033
crossref_primary_10_1002_clt2_12328
crossref_primary_10_1007_s00403_024_02966_6
crossref_primary_10_1016_j_bcp_2024_116164
crossref_primary_10_1007_s13555_024_01173_5
crossref_primary_10_1038_s43856_023_00404_8
crossref_primary_10_1093_ced_llae441
crossref_primary_10_1002_jvc2_103
crossref_primary_10_3389_fimmu_2022_933312
crossref_primary_10_3389_jcia_2024_12689
crossref_primary_10_1007_s12325_023_02724_6
crossref_primary_10_1016_j_jaip_2025_06_014
crossref_primary_10_1016_j_jaip_2025_06_019
crossref_primary_10_1111_cea_14402
crossref_primary_10_1016_j_jaip_2022_02_039
crossref_primary_10_1001_jamadermatol_2025_0733
crossref_primary_10_3390_biology11030433
crossref_primary_10_1080_1744666X_2022_2101999
crossref_primary_10_1136_bcr_2024_261489
crossref_primary_10_1016_j_jaip_2024_05_043
crossref_primary_10_1016_j_anai_2024_10_026
crossref_primary_10_1016_j_jaip_2023_04_050
crossref_primary_10_1016_j_anai_2022_02_006
crossref_primary_10_1007_s12325_021_01999_x
crossref_primary_10_1002_iid3_70132
crossref_primary_10_4103_idoj_idoj_156_25
crossref_primary_10_3390_life13061280
crossref_primary_10_1371_journal_pone_0279566
crossref_primary_10_1080_09546634_2025_2506672
crossref_primary_10_2500_aap_2023_44_230011
crossref_primary_10_3390_ijms24044039
crossref_primary_10_1016_j_jaip_2023_03_025
crossref_primary_10_1016_j_paed_2024_03_001
crossref_primary_10_1016_j_jacig_2024_100389
crossref_primary_10_1016_j_waojou_2023_100858
crossref_primary_10_1016_S0140_6736_24_00852_3
crossref_primary_10_1111_cod_14354
crossref_primary_10_1016_j_neurad_2025_101355
crossref_primary_10_1111_srt_13749
crossref_primary_10_1002_psp4_70098
crossref_primary_10_1016_j_mcna_2023_05_018
crossref_primary_10_1111_ijd_17707
crossref_primary_10_1111_pai_13982
crossref_primary_10_1002_clt2_12226
crossref_primary_10_1002_clt2_12227
crossref_primary_10_1002_clt2_12343
crossref_primary_10_1111_all_15810
crossref_primary_10_1111_exd_14602
crossref_primary_10_1016_j_jdcr_2022_05_011
crossref_primary_10_1016_j_abd_2024_02_006
crossref_primary_10_1016_j_anai_2024_05_020
crossref_primary_10_1016_j_medcle_2023_06_030
crossref_primary_10_1016_j_medcli_2023_06_026
crossref_primary_10_1097_ACI_0000000000000900
crossref_primary_10_1111_all_15813
crossref_primary_10_1007_s00403_024_03447_6
crossref_primary_10_1016_j_anai_2022_08_996
crossref_primary_10_1002_jvc2_283
crossref_primary_10_1111_cea_14586
crossref_primary_10_3390_ijms231911591
crossref_primary_10_1007_s40521_025_00391_2
crossref_primary_10_1136_bmjopen_2024_091482
crossref_primary_10_1016_j_jaci_2024_05_026
crossref_primary_10_1111_cea_14462
crossref_primary_10_1111_dth_15680
crossref_primary_10_1016_j_iac_2024_03_010
crossref_primary_10_1002_jvc2_46
crossref_primary_10_3389_fmicb_2023_1189484
crossref_primary_10_1080_17512433_2024_2401093
crossref_primary_10_1111_cea_70100
crossref_primary_10_1186_s13223_024_00931_6
crossref_primary_10_4103_ijd_ijd_722_23
crossref_primary_10_1080_15592294_2025_2503126
crossref_primary_10_1016_j_abd_2025_501147
crossref_primary_10_1093_ced_llac054
crossref_primary_10_1093_ced_llad386
crossref_primary_10_1111_pai_13736
crossref_primary_10_3390_jcm13061647
crossref_primary_10_25259_IJDVL_1218_2023
crossref_primary_10_3390_ijms25094658
crossref_primary_10_1002_clt2_12335
crossref_primary_10_1111_exd_14832
crossref_primary_10_1016_j_iac_2024_03_005
crossref_primary_10_1016_j_anai_2024_11_011
crossref_primary_10_1016_j_iac_2024_03_004
crossref_primary_10_4168_aair_2023_15_1_32
crossref_primary_10_1016_j_iac_2024_03_003
crossref_primary_10_1002_clt2_12342
crossref_primary_10_1016_j_pop_2022_11_003
crossref_primary_10_1111_cea_14457
crossref_primary_10_1016_j_iac_2024_03_008
crossref_primary_10_1016_j_iac_2024_03_007
crossref_primary_10_1016_j_diagmicrobio_2024_116292
crossref_primary_10_1146_annurev_pharmtox_051623_091038
crossref_primary_10_1159_000540155
crossref_primary_10_1016_j_iac_2024_03_001
crossref_primary_10_1016_j_reval_2022_07_008
crossref_primary_10_1111_cod_14331
crossref_primary_10_1111_jdv_20249
crossref_primary_10_1016_j_reval_2025_104242
crossref_primary_10_1111_1346_8138_17024
crossref_primary_10_1111_ped_70180
crossref_primary_10_1159_000535932
crossref_primary_10_1080_14656566_2024_2345731
crossref_primary_10_1093_ced_llae368
crossref_primary_10_1097_ACI_0000000000000927
crossref_primary_10_1371_journal_pone_0326445
crossref_primary_10_1089_derm_2025_0089
crossref_primary_10_1016_j_jaip_2024_06_014
crossref_primary_10_1093_ced_llae252
crossref_primary_10_1016_j_jaci_2025_07_019
crossref_primary_10_1016_j_jim_2024_113679
crossref_primary_10_1111_all_15957
crossref_primary_10_1016_j_waojou_2023_100784
crossref_primary_10_1002_jvc2_140
crossref_primary_10_1016_j_clim_2023_109247
crossref_primary_10_1016_j_jaip_2025_07_019
crossref_primary_10_3389_fimmu_2024_1458839
crossref_primary_10_1155_dth_8754260
crossref_primary_10_1007_s40521_024_00372_x
crossref_primary_10_3390_vaccines12060562
crossref_primary_10_1159_000530494
crossref_primary_10_1016_j_ad_2023_08_015
crossref_primary_10_1111_pai_13751
crossref_primary_10_4103_ijd_ijd_1085_23
crossref_primary_10_3390_jox14010024
crossref_primary_10_1111_srt_13731
crossref_primary_10_3390_molecules28165979
crossref_primary_10_1016_j_anai_2024_11_028
crossref_primary_10_1111_all_15843
crossref_primary_10_5415_apallergy_0000000000000184
crossref_primary_10_7759_cureus_90197
crossref_primary_10_1002_ccr3_7704
crossref_primary_10_1093_ced_llaf110
crossref_primary_10_3390_jcm13247552
crossref_primary_10_1016_j_waojou_2024_100950
crossref_primary_10_2147_CCID_S474422
crossref_primary_10_1016_j_hermed_2025_101046
crossref_primary_10_3390_diseases11040143
crossref_primary_10_1016_j_fander_2025_04_001
crossref_primary_10_1016_j_jaip_2025_07_008
crossref_primary_10_1016_j_reval_2025_104255
crossref_primary_10_3390_jcm11154453
crossref_primary_10_29254_2077_4214_2023_2_169_185_196
crossref_primary_10_1016_j_anai_2024_04_023
crossref_primary_10_1007_s40521_024_00380_x
crossref_primary_10_2500_aap_2024_45_240034
crossref_primary_10_1111_1346_8138_17480
crossref_primary_10_1136_bmjopen_2024_085041
crossref_primary_10_1016_j_jaip_2024_03_019
crossref_primary_10_1111_jdv_19637
crossref_primary_10_1186_s12913_025_13043_7
crossref_primary_10_1177_14034948251333901
crossref_primary_10_1002_clt2_70038
crossref_primary_10_1080_09546634_2025_2517384
crossref_primary_10_1093_ced_llae145
crossref_primary_10_2500_aap_2024_45_240037
crossref_primary_10_4081_dr_2023_9819
crossref_primary_10_1007_s00403_025_03968_8
crossref_primary_10_3389_fimmu_2023_1268467
crossref_primary_10_1016_j_waojou_2025_101098
crossref_primary_10_1016_j_jaip_2022_07_037
crossref_primary_10_1111_cea_70095
crossref_primary_10_1016_j_jaci_2022_10_004
crossref_primary_10_1016_j_jaci_2025_01_045
crossref_primary_10_1093_omcr_omaf118
crossref_primary_10_1016_j_jaip_2024_03_010
crossref_primary_10_2340_actadv_v104_36122
crossref_primary_10_3390_medicina58060816
crossref_primary_10_1159_000548067
crossref_primary_10_1111_ijd_16526
crossref_primary_10_2500_aap_2024_45_240041
crossref_primary_10_26641_2307_0404_2023_3_288930
crossref_primary_10_3390_jcm12093134
crossref_primary_10_3389_fimmu_2023_1279139
crossref_primary_10_1001_jama_2024_23974
crossref_primary_10_1016_j_jaip_2023_02_041
crossref_primary_10_1016_j_jval_2025_02_010
crossref_primary_10_5415_apallergy_0000000000000162
crossref_primary_10_1016_j_anai_2024_12_008
crossref_primary_10_1016_j_jaci_2022_10_017
crossref_primary_10_1016_j_jconrel_2025_02_029
crossref_primary_10_3389_fcvm_2025_1542223
crossref_primary_10_1007_s13555_023_01040_9
crossref_primary_10_1016_j_jaci_2022_10_016
crossref_primary_10_1111_imr_13380
crossref_primary_10_2340_actadv_v105_43568
crossref_primary_10_1016_j_jaci_2022_10_014
crossref_primary_10_1016_j_jaip_2025_05_033
crossref_primary_10_1016_j_jdcr_2022_12_009
crossref_primary_10_1007_s12016_022_08952_y
crossref_primary_10_1002_clt2_70052
crossref_primary_10_1007_s12026_024_09501_9
crossref_primary_10_1002_clt2_70053
crossref_primary_10_1111_pde_15020
crossref_primary_10_1111_phpp_70050
crossref_primary_10_29262_ram_v72i2_1452
crossref_primary_10_1111_jdv_19976
crossref_primary_10_1016_j_radcr_2024_10_004
crossref_primary_10_1007_s13555_021_00641_6
crossref_primary_10_5415_apallergy_0000000000000132
crossref_primary_10_1016_j_waojou_2025_101081
crossref_primary_10_1002_clt2_12295
crossref_primary_10_3390_jcm11071822
crossref_primary_10_2340_actadv_v104_24050
crossref_primary_10_1016_j_jaip_2023_01_022
crossref_primary_10_3389_fimmu_2024_1399459
crossref_primary_10_1016_j_jaip_2023_01_025
crossref_primary_10_1111_cea_14246
crossref_primary_10_1007_s40271_024_00725_3
crossref_primary_10_1056_NEJMoa2408792
crossref_primary_10_1007_s00105_024_05304_z
crossref_primary_10_1111_cea_14121
crossref_primary_10_1002_clt2_12290
crossref_primary_10_1016_j_waojou_2024_100984
crossref_primary_10_1007_s12519_022_00641_2
crossref_primary_10_21518_ms2025_191
crossref_primary_10_1007_s40521_024_00370_z
crossref_primary_10_1111_all_16175
crossref_primary_10_1111_jdv_20830
crossref_primary_10_7759_cureus_81443
crossref_primary_10_3390_biomedicines13082014
crossref_primary_10_1002_clt2_70069
crossref_primary_10_1016_j_waojou_2025_101072
crossref_primary_10_1186_s12962_025_00643_7
crossref_primary_10_36469_jheor_2024_117589
crossref_primary_10_2147_JAA_S402165
crossref_primary_10_1002_clt2_12279
crossref_primary_10_1007_s15012_024_8542_1
crossref_primary_10_1016_j_waojou_2025_101071
crossref_primary_10_1093_milmed_usad361
crossref_primary_10_1097_MJT_0000000000001691
crossref_primary_10_1016_j_waojou_2025_101068
crossref_primary_10_1007_s40629_023_00278_1
crossref_primary_10_1089_ped_2024_0070
crossref_primary_10_2340_actadv_v105_44312
crossref_primary_10_1016_j_jaip_2025_05_051
crossref_primary_10_1016_j_lfs_2024_122582
crossref_primary_10_1007_s13555_025_01461_8
crossref_primary_10_3390_jcm12072639
crossref_primary_10_4103_ds_DS_D_24_00192
crossref_primary_10_3389_fpubh_2023_1098066
crossref_primary_10_1016_j_xjidi_2025_100405
crossref_primary_10_3389_fphar_2023_1200252
crossref_primary_10_3390_ijms241411328
crossref_primary_10_1155_2022_2094589
crossref_primary_10_1111_dth_15838
crossref_primary_10_1007_s13555_023_00955_7
crossref_primary_10_1016_j_pop_2025_05_010
crossref_primary_10_4103_ijd_ijd_1199_23
crossref_primary_10_1093_ced_llae074
crossref_primary_10_1007_s15007_023_5823_7
crossref_primary_10_1016_j_jaip_2024_04_027
crossref_primary_10_1002_clt2_12195
crossref_primary_10_2478_aoas_2025_0063
crossref_primary_10_1007_s00403_025_04272_1
crossref_primary_10_3389_fmed_2024_1328765
crossref_primary_10_1016_j_jaip_2023_03_058
crossref_primary_10_1097_MD_0000000000042819
crossref_primary_10_1186_s12974_025_03397_4
crossref_primary_10_3390_jcm12010378
crossref_primary_10_1016_j_rxeng_2024_03_012
crossref_primary_10_1111_ijd_17547
crossref_primary_10_36290_med_2022_031
crossref_primary_10_1111_jdv_18574
crossref_primary_10_1111_cea_70067
crossref_primary_10_3390_ijerph21070934
crossref_primary_10_1111_all_16194
crossref_primary_10_1111_jdv_20772
crossref_primary_10_1097_jdpa_0000000000000026
crossref_primary_10_1002_clt2_70002
crossref_primary_10_1002_clt2_70005
crossref_primary_10_1080_14656566_2022_2128671
crossref_primary_10_3390_jcm13102967
crossref_primary_10_1016_j_jaip_2025_06_021
crossref_primary_10_1016_j_ad_2023_05_008
crossref_primary_10_1080_03007995_2024_2354534
crossref_primary_10_3390_jcm13154287
crossref_primary_10_1056_NEJMra2120166
crossref_primary_10_1093_bjd_ljae264
crossref_primary_10_1186_s13223_023_00820_4
crossref_primary_10_2340_actadv_v103_11627
crossref_primary_10_1016_j_anai_2022_08_003
crossref_primary_10_1016_j_iac_2025_06_009
crossref_primary_10_1016_j_jaip_2023_02_006
crossref_primary_10_1111_ijd_17653
crossref_primary_10_3390_biomedicines11051266
crossref_primary_10_1016_j_jaip_2023_03_047
crossref_primary_10_1159_000531966
crossref_primary_10_3390_jcm13226812
crossref_primary_10_1016_j_waojou_2024_100896
crossref_primary_10_1007_s40267_023_01016_x
crossref_primary_10_1016_j_waojou_2024_100898
crossref_primary_10_3390_medicina59040644
crossref_primary_10_1111_jdv_20523
crossref_primary_10_1111_ddg_15034
crossref_primary_10_1002_clt2_70016
crossref_primary_10_1007_s11882_024_01160_y
crossref_primary_10_1002_jvc2_70062
crossref_primary_10_1080_09603123_2025_2472191
crossref_primary_10_1111_pai_13925
crossref_primary_10_1016_j_mcna_2023_08_004
crossref_primary_10_3390_biomedicines11020410
crossref_primary_10_3390_life13041021
crossref_primary_10_1089_ped_2024_0022
crossref_primary_10_1056_NEJMc2212742
crossref_primary_10_23736_S2784_8671_25_08144_7
crossref_primary_10_1007_s00403_025_04328_2
crossref_primary_10_1007_s40257_024_00902_y
crossref_primary_10_1016_j_ad_2024_08_014
crossref_primary_10_4103_ijd_ijd_307_22
crossref_primary_10_2500_aap_2022_43_220068
crossref_primary_10_1159_000540684
crossref_primary_10_1007_s00105_024_05346_3
crossref_primary_10_1007_s13555_025_01498_9
crossref_primary_10_1016_j_jaci_2023_12_008
crossref_primary_10_1007_s13555_025_01376_4
crossref_primary_10_1002_clt2_70026
crossref_primary_10_1002_clt2_70027
crossref_primary_10_1007_s40257_023_00761_z
crossref_primary_10_1016_S0140_6736_23_01684_7
crossref_primary_10_1093_bjd_ljae038
crossref_primary_10_1007_s15011_024_6493_9
crossref_primary_10_1186_s12948_021_00165_6
crossref_primary_10_1093_bjd_ljae165
crossref_primary_10_1001_jamadermatol_2024_2056
crossref_primary_10_1111_ddg_14906_g
crossref_primary_10_3389_fimmu_2022_879754
crossref_primary_10_1136_bmjment_2025_301588
crossref_primary_10_3389_fped_2023_1239365
crossref_primary_10_1016_j_jaip_2023_07_030
crossref_primary_10_3389_fimmu_2025_1502325
crossref_primary_10_1016_j_imlet_2023_11_008
crossref_primary_10_7326_M23_1043
crossref_primary_10_3390_jcm13020477
crossref_primary_10_1007_s40257_022_00735_7
crossref_primary_10_3390_biomedicines11082232
crossref_primary_10_2147_JAA_S379912
crossref_primary_10_2500_aap_2023_44_220093
crossref_primary_10_3389_fnins_2022_1026200
crossref_primary_10_2147_JAA_S424360
crossref_primary_10_3390_life14020164
crossref_primary_10_1111_ijd_17102
crossref_primary_10_3390_ph15101246
crossref_primary_10_1186_s12913_025_13122_9
crossref_primary_10_1111_all_16670
crossref_primary_10_1155_2022_7468453
crossref_primary_10_1111_1346_8138_16562
crossref_primary_10_1111_jdv_19904
crossref_primary_10_1038_s41572_022_00389_z
crossref_primary_10_1016_j_asjsur_2024_05_093
crossref_primary_10_1111_all_15585
crossref_primary_10_1111_all_15227
crossref_primary_10_3389_fmed_2022_875492
crossref_primary_10_1016_j_jaip_2022_09_038
crossref_primary_10_1016_j_reval_2022_02_229
crossref_primary_10_1007_s40266_023_01010_y
crossref_primary_10_1007_s12519_023_00760_4
crossref_primary_10_1016_j_jaci_2024_01_032
crossref_primary_10_1080_19490976_2024_2382774
crossref_primary_10_3390_life13010152
crossref_primary_10_1089_ped_2024_0135
crossref_primary_10_3390_ijms25042026
crossref_primary_10_1038_s41598_025_94841_1
crossref_primary_10_1097_CM9_0000000000003170
crossref_primary_10_1111_all_70047
crossref_primary_10_1177_12034754231222415
crossref_primary_10_4168_aair_2023_15_4_496
crossref_primary_10_1016_j_abdp_2025_501147
crossref_primary_10_1080_1744666X_2023_2214729
crossref_primary_10_2147_JPR_S435991
crossref_primary_10_2478_jce_2025_0016
crossref_primary_10_3389_fimmu_2023_1213138
crossref_primary_10_1111_all_16446
crossref_primary_10_1016_j_waojou_2025_101116
crossref_primary_10_1007_s40265_025_02170_4
crossref_primary_10_30621_jbachs_1210134
crossref_primary_10_1111_ijd_17366
crossref_primary_10_3390_ph17030360
crossref_primary_10_4081_dr_2023_9763
crossref_primary_10_3390_jcm13185610
crossref_primary_10_1080_13543784_2022_2042513
crossref_primary_10_3389_falgy_2025_1568670
crossref_primary_10_1016_j_jaci_2022_08_027
crossref_primary_10_1159_000530610
crossref_primary_10_1111_all_16458
crossref_primary_10_1093_bjd_ljad426
crossref_primary_10_3390_ijms25179281
crossref_primary_10_1111_all_16334
crossref_primary_10_2340_actadv_v103_23932
crossref_primary_10_1007_s00403_025_04051_y
crossref_primary_10_1016_j_anai_2023_08_001
crossref_primary_10_1007_s12325_025_03172_0
crossref_primary_10_1016_j_reval_2023_103328
crossref_primary_10_1080_1744666X_2024_2388689
crossref_primary_10_1186_s12879_025_11484_3
crossref_primary_10_1007_s40521_024_00369_6
crossref_primary_10_4103_ijd_ijd_543_22
crossref_primary_10_1177_1721727X241238954
crossref_primary_10_1111_1346_8138_16779
crossref_primary_10_1177_21526575221144951
crossref_primary_10_1016_j_jaip_2023_07_002
crossref_primary_10_4168_aair_2024_16_6_626
crossref_primary_10_1002_clt2_70072
crossref_primary_10_1002_clt2_70075
crossref_primary_10_1016_j_jaip_2023_08_033
crossref_primary_10_1016_j_ad_2022_10_044
crossref_primary_10_1159_000534020
crossref_primary_10_1007_s00210_024_03571_0
crossref_primary_10_1016_j_jaip_2025_04_021
crossref_primary_10_1016_j_jaip_2024_03_050
crossref_primary_10_4103_ijd_ijd_112_23
crossref_primary_10_1111_1346_8138_17838
crossref_primary_10_1155_2023_2917144
crossref_primary_10_1080_14740338_2023_2262377
crossref_primary_10_1016_j_cca_2025_120233
crossref_primary_10_3389_fneur_2023_1263753
crossref_primary_10_3390_jcm12103561
crossref_primary_10_1080_14712598_2024_2354380
crossref_primary_10_1016_j_jaip_2023_09_002
crossref_primary_10_1111_jdv_19940
crossref_primary_10_1159_000536579
crossref_primary_10_3390_immuno5040044
crossref_primary_10_1016_j_jaip_2023_08_029
crossref_primary_10_1016_j_anai_2022_11_007
crossref_primary_10_1007_s00403_024_03123_9
crossref_primary_10_1155_dth_1564070
crossref_primary_10_1080_1744666X_2022_2138347
crossref_primary_10_1111_all_15262
crossref_primary_10_1111_all_16239
crossref_primary_10_3389_fphar_2023_1112917
crossref_primary_10_1111_all_16113
crossref_primary_10_3390_biomedicines12122765
crossref_primary_10_1007_s00431_023_05324_2
crossref_primary_10_1111_all_16598
crossref_primary_10_3390_biomedicines10112874
crossref_primary_10_1159_000547103
crossref_primary_10_3389_fmed_2025_1498795
crossref_primary_10_1007_s11882_024_01147_9
crossref_primary_10_3390_antiox11081590
crossref_primary_10_1016_j_bbih_2025_101088
crossref_primary_10_1016_j_jaip_2023_08_020
crossref_primary_10_1002_eji_70010
crossref_primary_10_1016_j_jaip_2022_07_003
crossref_primary_10_1016_j_jaip_2023_09_010
crossref_primary_10_1111_ijd_17016
crossref_primary_10_1016_j_jaip_2025_02_009
crossref_primary_10_1080_1750743X_2025_2510892
crossref_primary_10_1111_ddg_14932
crossref_primary_10_1007_s13555_024_01231_y
crossref_primary_10_1016_j_jaci_2025_03_007
crossref_primary_10_1016_j_anai_2023_07_019
crossref_primary_10_1111_jdv_70027
crossref_primary_10_1007_s40261_024_01389_5
crossref_primary_10_1007_s12016_025_09027_4
crossref_primary_10_7759_cureus_53125
crossref_primary_10_1111_all_15273
crossref_primary_10_1111_all_16482
crossref_primary_10_1016_j_jid_2022_12_005
crossref_primary_10_1111_all_16127
crossref_primary_10_7759_cureus_19371
crossref_primary_10_1016_j_jaip_2024_01_022
crossref_primary_10_1097_ASW_0000000000000118
crossref_primary_10_1111_pde_15738
crossref_primary_10_1016_j_jaip_2022_07_018
crossref_primary_10_1111_ddg_14906
crossref_primary_10_1016_j_abdp_2025_501198
crossref_primary_10_1016_j_jaip_2022_07_017
crossref_primary_10_3390_ph17111499
crossref_primary_10_1016_j_jaip_2022_07_011
crossref_primary_10_1056_NEJMcps2308355
crossref_primary_10_1016_j_jaci_2024_01_028
crossref_primary_10_3390_jcm14041375
crossref_primary_10_1111_all_15287
crossref_primary_10_1016_j_intimp_2023_110577
crossref_primary_10_1016_j_intimp_2024_111602
crossref_primary_10_1111_all_16250
crossref_primary_10_1111_all_16371
crossref_primary_10_3390_children11010086
crossref_primary_10_3390_ijms252212143
crossref_primary_10_1007_s00403_024_03629_2
crossref_primary_10_1111_all_16256
crossref_primary_10_1016_j_ad_2024_12_023
crossref_primary_10_3390_diagnostics15050608
crossref_primary_10_1097_MD_0000000000042640
crossref_primary_10_1080_13880209_2023_2169468
crossref_primary_10_1371_journal_pone_0295791
crossref_primary_10_1097_CM9_0000000000003593
crossref_primary_10_1371_journal_pmed_1004326
crossref_primary_10_25259_IJDVL_727_2023
crossref_primary_10_3390_jcm12185957
crossref_primary_10_1111_1346_8138_17943
Cites_doi 10.2340/00015555-1434
10.1016/j.jaci.2011.06.010
10.1111/jdv.14384
10.1136/annrheumdis-2016-209686
10.1111/j.1398-9995.2010.02409.x
10.1111/ced.12107
10.1016/j.jaip.2021.03.049
10.1016/j.jaci.2006.04.003
10.1111/j.1398-9995.2009.02268.x
10.1159/000491530
10.1034/j.1398-9995.2000.00317.x
10.1111/all.13271
10.1007/BF00637746
10.1111/imr.12632
10.1111/pai.12460
10.1016/j.jaci.2017.04.050
10.1111/j.1365-2133.1989.tb04167.x
10.1111/1523-1747.ep12499960
10.1111/j.1398-9995.2008.01879.x
10.1159/000248580
10.1016/j.jaad.2008.07.016
10.1016/0091-6749(75)90078-0
10.1016/j.jaad.2006.04.078
10.1111/j.1365-2125.2007.02859.x
10.1111/j.1365-2230.2007.02512.x
10.1111/j.1398-9995.2007.01591.x
10.1016/j.jaci.2013.05.013
10.1111/pai.12910
10.1016/S0091-6749(99)70506-3
10.1136/bmj.328.7454.1490
10.1111/bjd.14203
10.1016/j.jaci.2016.05.026
10.1111/cea.13102
10.1111/bjd.19561
10.2340/00015555-2573
10.1016/S0190-9622(88)70137-1
10.1038/jid.2014.306
10.1097/ACI.0b013e32833c79d7
10.1016/j.anai.2016.01.016
10.1111/jdv.14034
10.1007/s00403-011-1203-3
10.1111/j.1398-9995.2011.02580.x
10.1016/j.reprotox.2008.05.053
10.1159/000487669
10.1002/hup.1184
10.1111/j.1398-9995.2009.02188.x
10.1067/mjd.2000.104517
10.1016/0140-6736(92)90666-Q
10.1016/S0091-6749(81)90209-8
10.1111/j.1398-9995.2009.02325.x
10.1111/j.1398-9995.1980.tb01728.x
10.2340/0001555575484487
10.1111/bjd.13621
10.2340/00015555-2941
10.1111/bjd.14768
10.1016/j.jaci.2014.08.025
10.1111/j.1525-1470.2009.00869.x
10.1155/2013/130905
10.1111/jdv.12739
10.1046/j.1365-2133.2000.03664.x
10.1111/all.12209
10.1001/jamadermatol.2013.8705
10.1016/j.jaci.2008.12.008
10.1016/j.jclinepi.2010.07.015
10.1111/j.1398-9995.2010.02496.x
10.1016/j.vhri.2016.07.008
10.1111/all.12870
10.1111/cea.12900
10.18176/jiaci.0179
10.1111/all.14037
10.1111/pai.12555
10.1111/jdv.13966
10.1111/j.1399-3038.2004.00167.x
10.1111/j.1399-3038.2010.01120.x
10.1111/j.1398-9995.2008.01913.x
10.1111/cea.12348
10.1016/j.jaci.2015.06.021
10.1111/cea.12944
10.1097/00000372-198912000-00003
10.1007/s12016-020-08794-6
10.1016/j.jaci.2017.06.032
10.1016/j.anai.2009.12.007
10.1016/j.jaci.2015.12.1342
10.1111/j.1398-9995.2008.01726.x
10.1111/ced.12547
10.1016/j.jaci.2017.01.042
10.1111/all.14757
10.1159/000507218
10.1046/j.1365-2133.1998.02033.x
10.1159/000023902
10.4168/aair.2017.9.3.212
10.1016/j.jaci.2006.12.658
10.1111/all.12313
10.1111/bjd.12991
10.1016/j.jaci.2017.10.018
10.1111/j.1365-2133.2004.06095.x
10.2340/00015555-0434
10.1155/2015/368053
10.1111/j.1398-9995.2009.02179.x
10.2165/00002018-200831090-00006
10.1111/j.1398-9995.2011.02570.x
10.2340/0001555565449450
10.1016/j.jaci.2017.01.043
10.1136/bmj.311.7001.376
10.1111/j.0736-8046.2004.21202.x
10.1111/j.1398-9995.2007.01620.x
10.1159/000321181
10.1111/bjd.19425
10.1056/NEJM199506293322608
10.1111/j.1468-3083.2009.03289.x
10.1007/s40257-015-0134-8
10.1007/978-3-642-85267-1_2
10.1111/ddg.14485
10.1007/s40273-016-0412-1
10.1001/jamadermatol.2017.3183
10.1111/j.1365-2222.2008.03110.x
10.1056/NEJMcp011186
10.2340/0001555557369370
10.1097/ACI.0000000000000163
10.1016/j.jaci.2009.11.047
10.1111/all.13209
10.1111/bjd.16379
10.1038/sj.bjp.0707002
10.1159/000320233
10.1111/j.1365-2125.2006.02810.x
10.1046/j.1365-2133.1997.d01-1168.x
10.1111/j.1365-2133.1981.tb15306.x
10.1111/jdv.14075
10.1111/j.1398-9995.2009.02178.x
10.1016/j.jaci.2011.04.038
10.1159/000292947
10.1016/j.jaip.2017.07.017
10.1034/j.1398-9995.2003.00091.x
10.2500/aap.2016.37.4010
10.1016/j.jdermsci.2014.04.007
10.1046/j.1365-2133.2003.05486.x
10.1111/all.13397
10.1016/j.jaci.2013.12.1076
10.2340/0001555576295297
10.1159/000246281
10.1056/NEJMoa1215372
10.1111/all.13414
10.2500/aap.2017.38.4050
10.1111/all.12884
10.1016/0091-6749(71)90083-2
ContentType Journal Article
Copyright 2021 GA²LEN. published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
2021 GA²LEN. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml – notice: 2021 GA²LEN. published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
– notice: 2021 GA²LEN. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
– notice: 2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Distributed under a Creative Commons Attribution 4.0 International License
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
1XC
DOI 10.1111/all.15090
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
Hyper Article en Ligne (HAL)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1398-9995
EndPage 766
ExternalDocumentID oai:HAL:hal-03982425v1
34536239
10_1111_all_15090
ALL15090
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Global Allergy and Asthma European Network (GA²LEN)
– fundername: European Dermatology Forum (EDF)
– fundername: Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs)
– fundername: Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI)
– fundername: European Academy of Allergology and Clinical Immunology (EAACI)
GroupedDBID .3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
24P
2WC
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8F7
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAKAS
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHEFC
AHMBA
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOETA
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
E3Z
EBS
EJD
EMOBN
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
P6G
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
TR2
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
Y6R
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAYXX
AIQQE
CITATION
O8X
AAHHS
ACCFJ
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
CGR
CUY
CVF
DIK
ECM
EIF
ESX
NPM
WRC
WUP
7T5
H94
K9.
7X8
1XC
ID FETCH-LOGICAL-c4220-7f701a6b2d05e3dd599d608a894bc39da61edb22ebfab4dcebbed5538efcb75d3
IEDL.DBID 24P
ISICitedReferencesCount 828
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000708958300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0105-4538
1398-9995
IngestDate Tue Oct 14 20:19:24 EDT 2025
Wed Oct 01 13:58:20 EDT 2025
Fri Oct 03 09:52:30 EDT 2025
Wed Feb 19 02:26:49 EST 2025
Sat Nov 29 04:10:40 EST 2025
Tue Nov 18 21:32:37 EST 2025
Sun Jul 06 04:46:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords consensus
angioedema
itch
wheal
urticaria
hives
mast cell
evidence-based
Language English
License Attribution-NonCommercial
2021 GA²LEN. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4220-7f701a6b2d05e3dd599d608a894bc39da61edb22ebfab4dcebbed5538efcb75d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-1466-8875
0000-0002-2775-3681
0000-0002-1230-7013
0000-0001-6436-2703
0000-0003-2899-5508
0000-0003-3504-2203
0000-0001-6842-1360
0000-0001-7402-6850
0000-0003-3392-6590
0000-0002-9868-6308
0000-0002-8726-6658
0000-0003-3215-3370
0000-0002-6304-0494
0000-0002-2202-2513
0000-0002-6566-4743
0000-0002-5713-5331
0000-0002-3091-7237
0000-0001-7075-2062
0000-0002-4070-9976
0000-0002-3524-9952
0000-0001-8710-0829
0000-0002-1569-6034
0000-0002-3476-1196
0000-0002-9595-6050
0000-0001-6599-9538
0000-0002-4121-481X
0000-0001-9785-6099
0000-0002-2996-8248
0000-0003-4532-1644
0000-0002-8277-1700
0000-0001-7919-8141
0000-0001-7852-3854
0000-0002-8940-038X
0000-0001-6485-3158
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.15090
PMID 34536239
PQID 2633103220
PQPubID 34098
PageCount 30
ParticipantIDs hal_primary_oai_HAL_hal_03982425v1
proquest_miscellaneous_2574399115
proquest_journals_2633103220
pubmed_primary_34536239
crossref_citationtrail_10_1111_all_15090
crossref_primary_10_1111_all_15090
wiley_primary_10_1111_all_15090_ALL15090
PublicationCentury 2000
PublicationDate March 2022
2022-03-00
20220301
2022-03
PublicationDateYYYYMMDD 2022-03-01
PublicationDate_xml – month: 03
  year: 2022
  text: March 2022
PublicationDecade 2020
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
– name: Zurich
PublicationTitle Allergy (Copenhagen)
PublicationTitleAlternate Allergy
PublicationYear 2022
Publisher Blackwell Publishing Ltd
Wiley
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley
References 2004; 21
2010; 10
2018; 282
2013; 68
2013; 368
2010; 104
2003; 58
2016; 31
2017; 153
2008; 31
2004; 328
2014; 133
2016; 37
1996; 76
2018; 48
2016; 34
2017; 73
2018; 175
2017; 72
2018; 6
2018; 177
2010; 20
2021; 76
2011; 128
2013; 2013
2015; 135
2015; 136
2018; 179
1980; 35
2017; 76
2011; 64
2008; 26
2011; 66
2009; 123
1988; 177
2007; 63
2007; 64
1989; 36
1989; 3
2018; 29
2009; 64
1988; 18
2006; 55
1998
2008; 59
2013; 93
2014; 150
1995; 311
1999; 103
1998; 138
2006; 117
2014; 44
1996; 97
2016; 11
2007; 150
2004; 151
1989; 120
2015; 2015
1996; 193
2017; 140
2017; 141
2018; 98
2016; 27
2016; 175
2016; 174
1995; 75
2007; 39
2017; 47
1981; 104
1971; 48
2000; 42
2014; 69
2020; 59
1998; 115
2016; 71
1995; 332
1975; 55
2014; 171
2007; 32
1992; 98
1985; 65
2017; 9
2011; 155
2011; 154
2010; 65
2017; 31
2015; 172
2015; 40
2017; 38
2000; 55
2002; 346
2011; 22
2010; 152
2018; 73
2016; 116
2008; 63
2011; 26
2021; 9
2009; 23
1997; 136
2015; 15
2015; 16
2017; 27
2010; 125
2020; 181
1981; 68
2021; 184
2015; 8
2012; 304
2009; 26
2017; 97
1989; 11
2007; 119
2015; 29
2013; 38
2003; 149
2020; 75
2004; 15
2021; 19
1992; 339
2015
2016; 138
2000; 143
2008; 88
2014
2013; 132
2016; 137
1977; 57
2014; 75
2009; 39
e_1_2_12_6_1
e_1_2_12_130_1
e_1_2_12_2_1
e_1_2_12_17_1
e_1_2_12_111_1
e_1_2_12_157_1
Maurer M (e_1_2_12_161_1) 2014
e_1_2_12_115_1
e_1_2_12_153_1
e_1_2_12_108_1
e_1_2_12_20_1
e_1_2_12_66_1
e_1_2_12_43_1
e_1_2_12_85_1
e_1_2_12_24_1
e_1_2_12_47_1
e_1_2_12_62_1
e_1_2_12_81_1
e_1_2_12_100_1
e_1_2_12_123_1
e_1_2_12_146_1
e_1_2_12_28_1
e_1_2_12_104_1
e_1_2_12_127_1
e_1_2_12_31_1
e_1_2_12_77_1
e_1_2_12_54_1
e_1_2_12_96_1
e_1_2_12_139_1
e_1_2_12_35_1
Asero R (e_1_2_12_129_1) 2010; 20
e_1_2_12_58_1
e_1_2_12_12_1
e_1_2_12_50_1
e_1_2_12_92_1
e_1_2_12_3_1
e_1_2_12_152_1
e_1_2_12_18_1
e_1_2_12_110_1
e_1_2_12_137_1
e_1_2_12_114_1
e_1_2_12_133_1
e_1_2_12_156_1
e_1_2_12_21_1
e_1_2_12_44_1
e_1_2_12_63_1
e_1_2_12_86_1
e_1_2_12_107_1
e_1_2_12_25_1
e_1_2_12_48_1
e_1_2_12_67_1
Nordic Cochrane Centre (e_1_2_12_9_1) 2014
Zuberbier T (e_1_2_12_68_1) 1995; 75
e_1_2_12_40_1
e_1_2_12_82_1
e_1_2_12_160_1
e_1_2_12_141_1
e_1_2_12_122_1
e_1_2_12_29_1
e_1_2_12_149_1
e_1_2_12_126_1
e_1_2_12_103_1
e_1_2_12_145_1
e_1_2_12_119_1
e_1_2_12_32_1
e_1_2_12_55_1
e_1_2_12_74_1
e_1_2_12_97_1
Ishaq S (e_1_2_12_65_1) 2015; 8
e_1_2_12_36_1
e_1_2_12_59_1
e_1_2_12_78_1
e_1_2_12_13_1
e_1_2_12_7_1
(e_1_2_12_11_1) 2015
e_1_2_12_51_1
e_1_2_12_70_1
e_1_2_12_93_1
Kontou‐Fili KM (e_1_2_12_89_1) 1989; 3
e_1_2_12_4_1
Staubach P (e_1_2_12_60_1) 2021; 19
e_1_2_12_151_1
e_1_2_12_19_1
e_1_2_12_38_1
e_1_2_12_136_1
e_1_2_12_159_1
Bruno G (e_1_2_12_69_1) 1998
e_1_2_12_132_1
e_1_2_12_113_1
e_1_2_12_155_1
e_1_2_12_41_1
e_1_2_12_87_1
e_1_2_12_106_1
e_1_2_12_22_1
e_1_2_12_64_1
e_1_2_12_45_1
e_1_2_12_26_1
e_1_2_12_83_1
e_1_2_12_49_1
Zuberbier T (e_1_2_12_73_1) 1995; 75
e_1_2_12_121_1
e_1_2_12_148_1
e_1_2_12_102_1
e_1_2_12_125_1
e_1_2_12_144_1
e_1_2_12_52_1
e_1_2_12_98_1
e_1_2_12_118_1
e_1_2_12_33_1
e_1_2_12_56_1
e_1_2_12_37_1
e_1_2_12_79_1
e_1_2_12_14_1
e_1_2_12_90_1
e_1_2_12_8_1
e_1_2_12_10_1
e_1_2_12_94_1
e_1_2_12_71_1
e_1_2_12_150_1
Hannuksela M (e_1_2_12_138_1) 1985; 65
e_1_2_12_5_1
Engin B (e_1_2_12_140_1) 2008; 88
e_1_2_12_16_1
e_1_2_12_112_1
e_1_2_12_135_1
e_1_2_12_158_1
e_1_2_12_39_1
e_1_2_12_116_1
e_1_2_12_131_1
e_1_2_12_154_1
e_1_2_12_42_1
e_1_2_12_88_1
e_1_2_12_109_1
e_1_2_12_128_1
e_1_2_12_23_1
e_1_2_12_46_1
Pfrommer CBR (e_1_2_12_75_1) 1996; 97
e_1_2_12_80_1
e_1_2_12_61_1
e_1_2_12_84_1
e_1_2_12_27_1
e_1_2_12_101_1
e_1_2_12_147_1
e_1_2_12_120_1
e_1_2_12_105_1
Laurberg G (e_1_2_12_142_1) 1977; 57
e_1_2_12_143_1
e_1_2_12_124_1
e_1_2_12_30_1
e_1_2_12_53_1
e_1_2_12_76_1
e_1_2_12_99_1
e_1_2_12_117_1
e_1_2_12_34_1
e_1_2_12_57_1
e_1_2_12_15_1
e_1_2_12_91_1
Pereira C (e_1_2_12_134_1) 2007; 39
e_1_2_12_72_1
e_1_2_12_95_1
References_xml – volume: 2015
  start-page: 1
  year: 2015
  end-page: 3
  article-title: Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies
  publication-title: Case Rep Med
– volume: 174
  start-page: 892
  issue: 4
  year: 2016
  end-page: 894
  article-title: ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real‐life clinical practice
  publication-title: Br J Dermatol
– volume: 143
  start-page: 365
  issue: 2
  year: 2000
  end-page: 372
  article-title: Randomized double‐blind study of cyclosporin in chronic ‘idiopathic’ urticaria
  publication-title: Br J Dermatol
– volume: 39
  start-page: 237
  issue: 7
  year: 2007
  end-page: 242
  article-title: Low‐dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria
  publication-title: Eur Ann Allergy Clin Immunol
– volume: 23
  start-page: 1088
  issue: 9
  year: 2009
  end-page: 1091
  article-title: The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo‐ controlled treatment with rupatadine 10 and 20 mg
  publication-title: J Eur Acad Dermatol Venereol
– volume: 31
  start-page: 1715
  issue: 10
  year: 2017
  end-page: 1721
  article-title: Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria
  publication-title: J Eur Acad Dermatol Venereol
– volume: 128
  start-page: 567
  issue: 3
  year: 2011
  end-page: 573
  article-title: A randomized, placebo‐controlled, dose‐ranging study of single‐dose omalizumab in patients with H‐1‐antihistamine‐refractory chronic idiopathic urticaria
  publication-title: J Allergy Clin Immunol
– volume: 88
  start-page: 247
  issue: 3
  year: 2008
  end-page: 251
  article-title: Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial
  publication-title: Acta Derm Venereol
– volume: 8
  start-page: 6
  issue: Suppl1
  year: 2015
  end-page: 14
  article-title: Helicobacter pylori and gastric cancer: a state of the art review
  publication-title: Gastroenerol Hepatol Bed Bench
– year: 2014
– volume: 64
  start-page: 401
  issue: 4
  year: 2011
  end-page: 406
  article-title: GRADE guidelines: 3. Rating the quality of evidence
  publication-title: J Clin Epidemiol
– volume: 65
  start-page: 1494
  issue: 11
  year: 2010
  end-page: 1495
  article-title: Antihistamine‐resistant urticaria factitia successfully treated with anti‐immunoglobulin E therapy
  publication-title: Allergy
– year: 1998
– volume: 104
  start-page: 369
  issue: 4
  year: 1981
  end-page: 381
  article-title: Recurrent urticaria: clinical investigation of 330 patients
  publication-title: Br J Dermatol
– volume: 304
  start-page: 257
  issue: 4
  year: 2012
  end-page: 262
  article-title: Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria
  publication-title: Arch Dermatol Res
– volume: 141
  start-page: 638
  year: 2017
  end-page: 649
  article-title: Omalizumab treatment in chronic inducible urticaria: a systematic review of published evidence
  publication-title: J Allergy Clin Immunol
– volume: 34
  start-page: 815
  issue: 8
  year: 2016
  end-page: 827
  article-title: Cost utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria
  publication-title: Pharmacoeconomics
– volume: 177
  start-page: 287
  issue: 5
  year: 1988
  end-page: 291
  article-title: Calcium antagonist in the treatment of symptomatic dermographism. Low‐dose and high‐dose studies with nifedipine
  publication-title: Dermatologica
– volume: 39
  start-page: 116
  issue: 1
  year: 2009
  end-page: 126
  article-title: Incremental build‐up food challenge–a new diagnostic approach to evaluate pseudoallergic reactions in chronic urticaria: a pilot study: stepwise food challenge in chronic urticaria
  publication-title: Clin Exp Allergy
– volume: 40
  start-page: 399
  issue: 4
  year: 2015
  end-page: 403
  article-title: Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism
  publication-title: Clin Exp Dermatol
– volume: 38
  start-page: 360
  issue: 4
  year: 2013
  end-page: 366
  article-title: A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism
  publication-title: Clin Exp Dermatol
– volume: 132
  start-page: 101
  issue: 1
  year: 2013
  end-page: 109
  article-title: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
  publication-title: J Allergy Clin Immunol
– volume: 11
  start-page: 57
  year: 2016
  end-page: 59
  article-title: Direct Medical Costs of Chronic Urticaria in a Private Health Organization of Buenos Aires, Argentina
  publication-title: Value Health Reg Issues
– volume: 15
  start-page: 253
  issue: 3
  year: 2004
  end-page: 260
  article-title: Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis–a pooled analysis of three studies
  publication-title: Pediatr Allergy Immunol
– volume: 76
  start-page: 942
  issue: 6
  year: 2017
  end-page: 947
  article-title: Diagnostic criteria for cryopyrin‐associated periodic syndrome (CAPS)
  publication-title: Ann Rheum Dis
– volume: 140
  start-page: 870
  issue: 3
  year: 2017
  end-page: 873
  article-title: Omalizumab is effective in symptomatic dermographism‐results of a randomized placebo‐controlled trial
  publication-title: J Allergy Clin Immunol
– volume: 63
  start-page: 8
  issue: Suppl 86
  year: 2008
  end-page: 160
  article-title: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
  publication-title: Allergy
– volume: 119
  start-page: 752
  issue: 3
  year: 2007
  end-page: 754
  article-title: Successful treatment of delayed pressure urticaria with anti‐TNF‐alpha
  publication-title: J Allergy Clin Immun
– volume: 71
  start-page: 780
  issue: 6
  year: 2016
  end-page: 802
  article-title: The definition, diagnostic testing, and management of chronic inducible urticarias ‐ The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision
  publication-title: Allergy
– volume: 141
  start-page: 1138
  issue: 3
  year: 2017
  end-page: 1139
  article-title: The XTEND‐CIU study: long term use of Omalizumab in Chronic Idiopathic Urticaria
  publication-title: J Allergy Clin Immunol
– volume: 65
  start-page: 138
  issue: 1
  year: 2010
  end-page: 139
  article-title: Efficacy of omalizumab in delayed pressure urticaria: a case report
  publication-title: Allergy
– volume: 27
  start-page: 55
  issue: 1
  year: 2016
  end-page: 61
  article-title: Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2–11 years
  publication-title: Pediatr Allergy Immunol
– volume: 135
  start-page: 407
  issue: 2
  year: 2015
  end-page: 412
  article-title: The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy
  publication-title: J Allergy Clin Immunol
– volume: 175
  start-page: 246
  issue: 4
  year: 2018
  end-page: 251
  article-title: Gastritis can cause and trigger chronic spontaneous urticaria independent of the presence of
  publication-title: Int Arch Allergy Immunol
– volume: 339
  start-page: 1078
  issue: 8801
  year: 1992
  end-page: 1080
  article-title: Plasmapheresis for severe, unremitting, chronic urticaria
  publication-title: Lancet
– volume: 140
  start-page: 864
  issue: 3
  year: 2017
  end-page: 867
  article-title: Omalizumab is effective in cold urticaria‐results of a randomized placebo‐controlled trial
  publication-title: J Allergy Clin Immunol
– volume: 9
  start-page: 2274
  year: 2021
  end-page: 2283
  article-title: Diagnostic workup in chronic spontaneous urticaria – what to test and why?
  publication-title: J Allergy Clin Immunol Pract
– volume: 97
  start-page: 524
  issue: 4
  year: 2017
  end-page: 525
  article-title: Treatment of refractory chronic spontaneous urticaria with adalimumab
  publication-title: Acta Derm Venereol
– volume: 26
  start-page: 19
  issue: 1
  year: 2008
  end-page: 23
  article-title: The safety of cetirizine during pregnancy. A prospective observational cohort study
  publication-title: Reprod Toxicol
– volume: 73
  start-page: 1145
  issue: 5
  year: 2018
  end-page: 1146
  article-title: Executive summary of the methods report for ‘The EAACI/GA(2) LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update’
  publication-title: Allergy
– volume: 10
  start-page: 362
  issue: 4
  year: 2010
  end-page: 369
  article-title: Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence‐based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system
  publication-title: Curr Opin Allergy Clin Immunol
– volume: 65
  start-page: 449
  issue: 5
  year: 1985
  end-page: 450
  article-title: Ultraviolet light therapy in chronic urticaria
  publication-title: Acta Derm Venereol
– volume: 55
  start-page: 705
  issue: 4
  year: 2006
  end-page: 709
  article-title: Cyclosporine in chronic idiopathic urticaria: a double‐blind, randomized, placebo‐controlled trial
  publication-title: J Am Acad Dermatol
– volume: 149
  start-page: 836
  issue: 4
  year: 2003
  end-page: 840
  article-title: Effect of high‐dose intravenous immunoglobulin in delayed pressure urticaria
  publication-title: Br J Dermatol
– volume: 55
  start-page: 394
  issue: 6
  year: 1975
  end-page: 402
  article-title: In vivo studies of mediator release in cold urticaria and cholinergic urticaria
  publication-title: J Allergy Clin Immunol
– volume: 66
  start-page: 1107
  issue: 8
  year: 2011
  end-page: 1113
  article-title: Basophil recruitment and activation in inflammatory skin diseases
  publication-title: Allergy
– start-page: 85
  year: 1998
  end-page: 89
– volume: 55
  start-page: 306
  issue: 3
  year: 2000
  end-page: 308
  article-title: Chronic urticaria: a mystery
  publication-title: Allergy
– volume: 328
  start-page: 1490
  issue: 7454
  year: 2004
  article-title: Grading quality of evidence and strength of recommendations
  publication-title: BMJ
– volume: 193
  start-page: 324
  issue: 4
  year: 1996
  end-page: 327
  article-title: Double‐blind crossover study of high‐dose cetirizine in cholinergic urticaria
  publication-title: Dermatology
– volume: 75
  start-page: 88
  issue: 2
  year: 2014
  end-page: 93
  article-title: Development of a standardized pulse‐controlled ergometry test for diagnosing and investigating cholinergic urticaria
  publication-title: J Dermatol Sci
– volume: 138
  start-page: 101
  issue: 1
  year: 1998
  end-page: 106
  article-title: Intravenous immunoglobulin in autoimmune chronic urticaria
  publication-title: Br J Dermatol
– volume: 123
  start-page: 672
  issue: 3
  year: 2009
  end-page: 679
  article-title: High‐dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard‐dose treatment in patients with acquired cold urticaria: a randomized, placebo‐controlled, crossover study
  publication-title: J Allergy Clin Immunol
– volume: 65
  start-page: 931
  issue: 7
  year: 2010
  end-page: 932
  article-title: Effective treatment of refractory severe heat urticaria with omalizumab
  publication-title: Allergy
– volume: 103
  start-page: 307
  issue: 2 Pt 1
  year: 1999
  end-page: 314
  article-title: Upregulation of TNF‐alpha and IL‐3 expression in lesional and uninvolved skin in different types of urticaria
  publication-title: J Allergy Clin Immunol
– volume: 3
  start-page: 23
  year: 1989
  end-page: 25
  article-title: Therapeutic effect of cetirizine 2 HCl in delayed pressure urticaria
  publication-title: Health Sci Rev
– volume: 179
  start-page: 210
  issue: 1
  year: 2018
  end-page: 212
  article-title: Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria
  publication-title: Br J Dermatol
– volume: 31
  start-page: 650
  issue: 4
  year: 2016
  end-page: 655
  article-title: A Popular myth ‐ low‐histamine diet improves chronic spontaneous urticaria ‐ fact or fiction?
  publication-title: J Eur Acad Dermatol Venereol
– volume: 93
  start-page: 168
  issue: 2
  year: 2013
  end-page: 174
  article-title: Can on‐demand non‐sedating antihistamines improve urticaria symptoms? A double‐blind, randomized, single‐dose study
  publication-title: Acta Derm Venereol
– volume: 59
  start-page: 38
  issue: 1
  year: 2020
  end-page: 45
  article-title: Omalizumab updosing in chronic spontaneous urticaria: an overview of real‐world evidence
  publication-title: Clin Rev Allergy Immunol
– volume: 64
  start-page: 605
  issue: 4
  year: 2009
  end-page: 612
  article-title: How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life
  publication-title: Allergy
– volume: 64
  start-page: 1417
  issue: 10
  year: 2009
  end-page: 1426
  article-title: EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria
  publication-title: Allergy
– volume: 177
  start-page: 360
  issue: 4
  year: 2018
  end-page: 364
  article-title: Omalizumab updosing for better disease control in chronic spontaneous urticaria patients
  publication-title: Int Arch Allergy Immunol
– volume: 21
  start-page: 102
  issue: 2
  year: 2004
  end-page: 108
  article-title: The etiology of different forms of urticaria in childhood
  publication-title: Pediatr Dermatol
– volume: 36
  start-page: 617
  issue: 6
  year: 1989
  end-page: 619
  article-title: Suppression of histamine‐induced skin reactions by loratadine and cetirizine diHCl
  publication-title: Eur J Clin Pharmacol
– volume: 73
  start-page: 251
  issue: 1
  year: 2017
  end-page: 255
  article-title: Comparison and interpretability of the available urticaria activity scores
  publication-title: Allergy
– volume: 135
  start-page: 67
  issue: 1
  year: 2015
  end-page: 75
  article-title: Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo‐controlled study
  publication-title: J Invest Dermatol
– volume: 31
  issue: 5
  year: 2017
  article-title: Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases
  publication-title: J Eur Acad Dermatol Venereol
– volume: 57
  start-page: 369
  issue: 4
  year: 1977
  end-page: 370
  article-title: Tranexamic acid (Cyklokapron) in chronic urticaria: a double‐blind study
  publication-title: Acta Derm Venereol
– volume: 63
  start-page: 247
  issue: 2
  year: 2008
  end-page: 249
  article-title: Successful treatment of cholinergic urticaria with anti‐immunoglobulin E therapy
  publication-title: Allergy
– volume: 29
  start-page: 630
  issue: 6
  year: 2018
  end-page: 636
  article-title: Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients
  publication-title: Pediatr Allergy Immunol
– volume: 98
  start-page: 800
  issue: 5
  year: 1992
  end-page: 804
  article-title: Anti‐inflammatory effect of cyclosporin A on human skin mast cells
  publication-title: J Invest Dermatol
– volume: 151
  start-page: 898
  issue: 4
  year: 2004
  end-page: 902
  article-title: Sodium benzoate‐induced repeated episodes of acute urticaria/angio‐oedema: randomized controlled trial
  publication-title: Br J Dermatol
– volume: 368
  start-page: 924
  issue: 10
  year: 2013
  end-page: 935
  article-title: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
  publication-title: N Engl J Med
– volume: 31
  start-page: 775
  issue: 9
  year: 2008
  end-page: 788
  article-title: Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta‐analysis
  publication-title: Drug Saf
– volume: 27
  start-page: 326
  issue: 5
  year: 2017
  end-page: 327
  article-title: Omalizumab as third‐line therapy for urticaria during pregnancy
  publication-title: J Investig Allergol Clin Immunol
– volume: 6
  start-page: 586
  year: 2018
  end-page: 599
  article-title: Cyclosporine for chronic spontaneous urticaria: a meta‐analysis and systematic review
  publication-title: J Allergy Clin Immunol Pract
– volume: 47
  start-page: 710
  issue: 6
  year: 2017
  end-page: 718
  article-title: How to manage chronic urticaria ‘beyond’ guidelines: a practical algorithm
  publication-title: Clin Exp Allergy
– volume: 181
  start-page: 321
  issue: 5
  year: 2020
  end-page: 333
  article-title: Urticaria: collegium internationale allergologicum (CIA) update 2020
  publication-title: Int Arch Allergy Immunol
– volume: 15
  start-page: 220
  issue: 3
  year: 2015
  end-page: 226
  article-title: Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema
  publication-title: Curr Opin Allergy Clin Immunol
– volume: 117
  start-page: 1415
  issue: 6
  year: 2006
  end-page: 1418
  article-title: Successful treatment of cold‐induced urticaria/anaphylaxis with anti‐IgE
  publication-title: J Allergy Clin Immunol
– volume: 68
  start-page: 438
  issue: 6
  year: 1981
  end-page: 441
  article-title: Identification of a new physically induced urticaria: cold‐induced cholinergic urticaria
  publication-title: J Allergy Clin Immunol
– volume: 184
  start-page: 167
  issue: 1
  year: 2021
  end-page: 168
  article-title: Omalizumab for the treatment of chronic inducible urticaria in 80 patients
  publication-title: Br J Dermatol
– volume: 16
  start-page: 313
  issue: 4
  year: 2015
  end-page: 321
  article-title: Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria
  publication-title: Am J Clin Dermatol
– volume: 11
  start-page: 528
  issue: 6
  year: 1989
  end-page: 533
  article-title: Incidence of leukocytoclastic vasculitis in chronic idiopathic urticaria. Study of 100 cases
  publication-title: Am J Dermatopathol
– volume: 38
  start-page: 222
  issue: 3
  year: 2017
  end-page: 230
  article-title: Randomized, placebo‐controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis
  publication-title: Allergy Asthma Proc
– volume: 42
  start-page: 1030
  issue: 6
  year: 2000
  end-page: 1032
  article-title: UVA rush hardening for the treatment of solar urticaria
  publication-title: J Am Acad Dermatol
– volume: 346
  start-page: 175
  issue: 3
  year: 2002
  end-page: 179
  article-title: Clinical practice. Chronic urticaria and angioedema
  publication-title: N Engl J Med
– volume: 75
  start-page: 484
  issue: 6
  year: 1995
  end-page: 487
  article-title: Pseudoallergen‐free diet in the treatment of chronic urticaria. A prospective study
  publication-title: Acta Derm Venereol
– volume: 27
  start-page: 493
  issue: 5
  year: 2016
  end-page: 498
  article-title: Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases
  publication-title: Pediatr Allergy Immunol
– volume: 152
  start-page: 384
  issue: 4
  year: 2010
  end-page: 389
  article-title: Heparin and tranexamic Acid therapy may be effective in treatment‐resistant chronic urticaria with elevated d‐dimer: a pilot study
  publication-title: Int Arch Allergy Immunol
– volume: 32
  start-page: 740
  issue: 6
  year: 2007
  end-page: 743
  article-title: Candida spp. colonization and serum anticandidal antibody levels in patients with chronic urticaria
  publication-title: Clin Exp Dermatol
– volume: 66
  start-page: 317
  issue: 3
  year: 2011
  end-page: 330
  article-title: Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report
  publication-title: Allergy
– volume: 154
  start-page: 177
  issue: 2
  year: 2011
  end-page: 180
  article-title: Anti‐immunoglobulin E treatment of patients with recalcitrant physical urticaria
  publication-title: Int Arch Allergy Immunol
– volume: 64
  start-page: 1427
  issue: 10
  year: 2009
  end-page: 1443
  article-title: EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria
  publication-title: Allergy
– volume: 26
  start-page: 409
  issue: 4
  year: 2009
  end-page: 413
  article-title: Experience with cyclosporine in children with chronic idiopathic urticaria
  publication-title: Pediatr Dermatol
– volume: 47
  start-page: 684
  issue: 5
  year: 2017
  end-page: 692
  article-title: H1‐antihistamine‐refractory chronic spontaneous urticaria: it's worse than we thought ‐ first results of the multicenter real‐life AWARE study
  publication-title: Clin Exp Allergy
– volume: 116
  start-page: 344
  issue: 4
  year: 2016
  end-page: 348
  article-title: Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria
  publication-title: Ann Allergy Asthma Immunol
– volume: 184
  start-page: 226
  issue: 2
  year: 2021
  end-page: 236
  article-title: The global burden of chronic urticaria for the patient and society
  publication-title: Br J Dermatol
– volume: 63
  start-page: 534
  issue: 5
  year: 2007
  end-page: 540
  article-title: Pharmacokinetics of desloratadine in children between 2 and 11 years of age
  publication-title: Br J Clin Pharmacol
– volume: 137
  start-page: 1742
  issue: 6
  year: 2016
  end-page: 1750
  article-title: Omalizumab for the treatment of chronic spontaneous urticaria: a meta‐analysis of randomized clinical trials
  publication-title: J Allergy Clin Immunol
– volume: 104
  start-page: 253
  issue: 3
  year: 2010
  end-page: 258
  article-title: Effect of high‐dose intravenous immunoglobulin treatment in therapy‐resistant chronic spontaneous urticaria
  publication-title: Ann Allergy Asthma Immunol
– volume: 75
  start-page: 484
  issue: 6
  year: 1995
  end-page: 487
  article-title: Pseudoallergen‐free diet in the treatment of chronic urticaria ‐ A prospective study
  publication-title: Acta Derm Venereol
– volume: 115
  start-page: 210
  issue: 3
  year: 1998
  end-page: 214
  article-title: Differential endothelial adhesion molecule expression in early and late whealing reactions
  publication-title: Int Arch Allergy Immunol
– volume: 133
  start-page: 1365
  issue: 5
  year: 2014
  end-page: 1372
  article-title: Development and validation of the Urticaria Control Test: a patient‐reported outcome instrument for assessing urticaria control
  publication-title: J Allergy Clin Immunol
– volume: 125
  start-page: 676
  issue: 3
  year: 2010
  end-page: 682
  article-title: The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult‐to‐treat urticaria
  publication-title: J Allergy Clin Immunol
– volume: 20
  start-page: 386
  issue: 5
  year: 2010
  end-page: 390
  article-title: Usefulness of a short course of oral prednisone in antihistamine‐resistant chronic urticaria: a retrospective analysis
  publication-title: J Invest Allerg Clin
– volume: 128
  start-page: 202
  issue: 1
  year: 2011
  end-page: 209
  article-title: Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase
  publication-title: J Allergy Clin Immunol
– volume: 66
  start-page: 840
  issue: 7
  year: 2011
  end-page: 844
  article-title: Recommendations for assessing patient‐reported outcomes and health‐related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper
  publication-title: Allergy
– volume: 69
  start-page: 868
  issue: 7
  year: 2014
  end-page: 887
  article-title: The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
  publication-title: Allergy
– volume: 2013
  start-page: 1
  year: 2013
  end-page: 4
  article-title: TNF‐alpha inhibitors for chronic urticaria: experience in 20 patients
  publication-title: J Allergy (Cairo)
– volume: 35
  start-page: 139
  issue: 2
  year: 1980
  end-page: 141
  article-title: Oral sodium cromoglycate in chronic urticaria
  publication-title: Allergy
– volume: 19
  start-page: 1013
  issue: 7
  year: 2021
  end-page: 1019
  article-title: Epidemiology of urticaria in German children
  publication-title: J Dtsch Dermatol Ges
– volume: 44
  start-page: 1053
  issue: 8
  year: 2014
  end-page: 1060
  article-title: Calcitonin gene‐related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria
  publication-title: Clin Exp Allergy
– volume: 136
  start-page: 197
  issue: 2
  year: 1997
  end-page: 201
  article-title: The impact of chronic urticaria on the quality of life
  publication-title: Br J Dermatol
– volume: 76
  start-page: 2965
  year: 2021
  end-page: 2981
  article-title: Predictors of treatment response in chronic spontaneous urticaria
  publication-title: Allergy
– volume: 68
  start-page: 1185
  issue: 9
  year: 2013
  end-page: 1192
  article-title: Development, validation and initial results of the angioedema activity score
  publication-title: Allergy
– volume: 26
  start-page: 133
  issue: 2
  year: 2011
  end-page: 139
  article-title: Brain histamine H1 receptor occupancy of loratadine measured by positron emission topography: comparison of H1 receptor occupancy and proportional impairment ratio
  publication-title: Hum Psychopharmacol
– volume: 150
  start-page: 509
  issue: 4
  year: 2007
  end-page: 518
  article-title: Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506
  publication-title: Br J Pharmacol
– volume: 76
  start-page: 295
  issue: 4
  year: 1996
  end-page: 297
  article-title: Acute urticaria: clinical aspects and therapeutic responsiveness
  publication-title: Acta Derm Venereol
– volume: 97
  issue: 367
  year: 1996
  article-title: Characterization of naturally occurring pseudoallergens causing chronic urticaria
  publication-title: J Allergy Clin Immunol
– volume: 120
  start-page: 403
  issue: 3
  year: 1989
  end-page: 408
  article-title: Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine
  publication-title: Br J Dermatol
– volume: 175
  start-page: 1153
  issue: 6
  year: 2016
  end-page: 1165
  article-title: Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta‐analysis
  publication-title: Br J Dermatol
– year: 2015
– volume: 9
  start-page: 212
  issue: 3
  year: 2017
  end-page: 219
  article-title: Prevalence and risk factors of urticaria with a focus on chronic urticaria in children
  publication-title: Allergy Asthma Immunol Res
– volume: 59
  start-page: 752
  issue: 5
  year: 2008
  end-page: 757
  article-title: Narrowband ultraviolet B phototherapy is beneficial in antihistamine‐resistant symptomatic dermographism: a pilot study
  publication-title: J Am Acad Dermatol
– volume: 48
  start-page: 433
  issue: 4
  year: 2018
  end-page: 444
  article-title: Development and validation of the Cholinergic Urticaria Quality‐of‐Life Questionnaire (CholU‐QoL)
  publication-title: Clin Exp Allergy
– volume: 150
  start-page: 288
  issue: 3
  year: 2014
  end-page: 290
  article-title: Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria
  publication-title: JAMA Dermatol
– volume: 29
  start-page: 2043
  issue: 10
  year: 2015
  end-page: 2045
  article-title: An improved Peltier effect‐based instrument for critical temperature threshold measurement in cold‐ and heat‐induced urticaria
  publication-title: J Eur Acad Dermatol Venereol
– volume: 138
  start-page: 1483
  issue: 5
  year: 2016
  end-page: 1485
  article-title: Antihistamine updosing reduces disease activity in patients with difficult‐to‐treat cholinergic urticaria
  publication-title: J Allergy Clin Immunol
– volume: 311
  start-page: 376
  issue: 7001
  year: 1995
  end-page: 380
  article-title: Consensus methods for medical and health services research
  publication-title: BMJ
– volume: 140
  start-page: 1710
  issue: 6
  year: 2017
  end-page: 1713
  article-title: Responsiveness and minimal important difference of the urticaria control test
  publication-title: J Allergy Clin Immunol
– volume: 22
  start-page: 1
  issue: 1 Pt 1
  year: 2011
  end-page: 8
  article-title: Chronic spontaneous urticaria in children: itching for insight
  publication-title: Pediatr Allergy Immunol
– volume: 136
  start-page: 245
  issue: 2
  year: 2015
  end-page: 251
  article-title: Approaches to the diagnosis and management of patients with a history of nonsteroidal anti‐inflammatory drug‐related urticaria and angioedema
  publication-title: J Allergy Clin Immunol
– volume: 128
  start-page: 567
  issue: 3
  year: 2011
  article-title: A randomized, placebo‐controlled, dose‐ranging study of single‐dose omalizumab in patients with H‐1‐antihistamine‐refractory chronic idiopathic urticaria
  publication-title: J Allergy Clin Immunol
– volume: 171
  start-page: 505
  issue: 3
  year: 2014
  end-page: 511
  article-title: Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low‐level persistence in uninvolved skin
  publication-title: Br J Dermatol
– volume: 37
  start-page: 450
  issue: 6
  year: 2016
  end-page: 457
  article-title: Clinical and etiologic evaluation of the children with chronic urticaria
  publication-title: Allergy Asthma Proc
– volume: 58
  start-page: 621
  issue: 7
  year: 2003
  end-page: 623
  article-title: Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy
  publication-title: Allergy
– volume: 69
  issue: 7
  year: 2014
  article-title: Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria
  publication-title: Allergy
– volume: 71
  start-page: 1135
  issue: 8
  year: 2016
  end-page: 1144
  article-title: Effect of omalizumab on angioedema in H1 ‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ACT, a randomized controlled trial
  publication-title: Allergy
– volume: 75
  start-page: 423
  issue: 2
  year: 2020
  end-page: 432
  article-title: Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta‐analysis
  publication-title: Allergy
– volume: 18
  start-page: 1289
  issue: 6
  year: 1988
  end-page: 1298
  article-title: Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients
  publication-title: J Am Acad Dermatol
– volume: 172
  start-page: 1294
  issue: 5
  year: 2015
  end-page: 1302
  article-title: Elevations in T‐helper‐2‐initiating cytokines (interleukin‐33, interleukin‐25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria
  publication-title: Br J Dermatol
– volume: 155
  start-page: 367
  issue: 4
  year: 2011
  end-page: 378
  article-title: Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease
  publication-title: Int Arch Allergy Immunol
– volume: 282
  start-page: 232
  issue: 1
  year: 2018
  end-page: 247
  article-title: The role and relevance of mast cells in urticaria
  publication-title: Immunol Rev
– volume: 73
  start-page: 1393
  issue: 7
  year: 2018
  end-page: 1414
  article-title: The EAACI/GA LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
  publication-title: Allergy
– volume: 64
  start-page: 174
  issue: 2
  year: 2007
  end-page: 184
  article-title: Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults
  publication-title: Br J Clin Pharmacol
– volume: 65
  start-page: 459
  issue: 4
  year: 2010
  end-page: 466
  article-title: Risk of first‐generation H(1)‐antihistamines: a GA(2)LEN position paper
  publication-title: Allergy
– volume: 63
  start-page: 1563
  issue: 11
  year: 2008
  end-page: 1565
  article-title: Successful treatment of solar urticaria with anti‐immunoglobulin E therapy
  publication-title: Allergy
– volume: 63
  start-page: 777
  issue: 6
  year: 2008
  end-page: 780
  article-title: How to assess disease activity in patients with chronic urticaria?
  publication-title: Allergy
– volume: 72
  start-page: 2005
  issue: 12
  year: 2017
  end-page: 2016
  article-title: The burden of chronic spontaneous urticaria is substantial: real‐world evidence from ASSURE‐CSU
  publication-title: Allergy
– volume: 31
  start-page: 1056
  issue: 6
  year: 2017
  end-page: 1063
  article-title: Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema
  publication-title: J Eur Acad Dermatol Venereol
– volume: 98
  start-page: 641
  issue: 7
  year: 2018
  end-page: 647
  article-title: Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment
  publication-title: Acta Derm Venereol
– volume: 48
  start-page: 366
  issue: 6
  year: 1971
  end-page: 371
  article-title: Treatment of cold urticaria with cyproheptadine
  publication-title: J Allergy Clin Immunol
– volume: 332
  start-page: 1767
  issue: 26
  year: 1995
  end-page: 1772
  article-title: Chronic urticaria
  publication-title: N Engl J Med
– volume: 153
  start-page: 1221
  issue: 12
  year: 2017
  end-page: 1222
  article-title: Chronic urticaria in children ‐ still itching for insight
  publication-title: JAMA Dermatol
– ident: e_1_2_12_83_1
  doi: 10.2340/00015555-1434
– ident: e_1_2_12_118_1
  doi: 10.1016/j.jaci.2011.06.010
– ident: e_1_2_12_114_1
  doi: 10.1111/jdv.14384
– volume-title: UpToDate
  year: 2014
  ident: e_1_2_12_161_1
– ident: e_1_2_12_61_1
  doi: 10.1136/annrheumdis-2016-209686
– ident: e_1_2_12_110_1
  doi: 10.1111/j.1398-9995.2010.02409.x
– ident: e_1_2_12_49_1
  doi: 10.1111/ced.12107
– ident: e_1_2_12_35_1
  doi: 10.1016/j.jaip.2021.03.049
– ident: e_1_2_12_106_1
  doi: 10.1016/j.jaci.2006.04.003
– ident: e_1_2_12_109_1
  doi: 10.1111/j.1398-9995.2009.02268.x
– ident: e_1_2_12_122_1
  doi: 10.1159/000491530
– ident: e_1_2_12_76_1
  doi: 10.1034/j.1398-9995.2000.00317.x
– ident: e_1_2_12_42_1
  doi: 10.1111/all.13271
– ident: e_1_2_12_87_1
  doi: 10.1007/BF00637746
– ident: e_1_2_12_14_1
  doi: 10.1111/imr.12632
– ident: e_1_2_12_153_1
  doi: 10.1111/pai.12460
– ident: e_1_2_12_44_1
  doi: 10.1016/j.jaci.2017.04.050
– ident: e_1_2_12_144_1
  doi: 10.1111/j.1365-2133.1989.tb04167.x
– ident: e_1_2_12_123_1
  doi: 10.1111/1523-1747.ep12499960
– ident: e_1_2_12_108_1
  doi: 10.1111/j.1398-9995.2008.01879.x
– ident: e_1_2_12_143_1
  doi: 10.1159/000248580
– ident: e_1_2_12_139_1
  doi: 10.1016/j.jaad.2008.07.016
– ident: e_1_2_12_91_1
  doi: 10.1016/0091-6749(75)90078-0
– ident: e_1_2_12_125_1
  doi: 10.1016/j.jaad.2006.04.078
– ident: e_1_2_12_150_1
  doi: 10.1111/j.1365-2125.2007.02859.x
– ident: e_1_2_12_67_1
  doi: 10.1111/j.1365-2230.2007.02512.x
– ident: e_1_2_12_105_1
  doi: 10.1111/j.1398-9995.2007.01591.x
– volume: 97
  issue: 367
  year: 1996
  ident: e_1_2_12_75_1
  article-title: Characterization of naturally occurring pseudoallergens causing chronic urticaria
  publication-title: J Allergy Clin Immunol
– ident: e_1_2_12_100_1
  doi: 10.1016/j.jaci.2013.05.013
– ident: e_1_2_12_58_1
  doi: 10.1111/pai.12910
– ident: e_1_2_12_23_1
  doi: 10.1016/S0091-6749(99)70506-3
– ident: e_1_2_12_7_1
– ident: e_1_2_12_10_1
  doi: 10.1136/bmj.328.7454.1490
– ident: e_1_2_12_28_1
  doi: 10.1111/bjd.14203
– ident: e_1_2_12_51_1
  doi: 10.1016/j.jaci.2016.05.026
– ident: e_1_2_12_52_1
  doi: 10.1111/cea.13102
– ident: e_1_2_12_25_1
  doi: 10.1111/bjd.19561
– ident: e_1_2_12_136_1
  doi: 10.2340/00015555-2573
– ident: e_1_2_12_145_1
  doi: 10.1016/S0190-9622(88)70137-1
– ident: e_1_2_12_98_1
  doi: 10.1038/jid.2014.306
– ident: e_1_2_12_64_1
  doi: 10.1097/ACI.0b013e32833c79d7
– ident: e_1_2_12_71_1
  doi: 10.1016/j.anai.2016.01.016
– ident: e_1_2_12_157_1
  doi: 10.1111/jdv.14034
– ident: e_1_2_12_79_1
  doi: 10.1007/s00403-011-1203-3
– ident: e_1_2_12_26_1
  doi: 10.1111/j.1398-9995.2011.02580.x
– ident: e_1_2_12_154_1
  doi: 10.1016/j.reprotox.2008.05.053
– ident: e_1_2_12_70_1
  doi: 10.1159/000487669
– ident: e_1_2_12_86_1
  doi: 10.1002/hup.1184
– ident: e_1_2_12_112_1
  doi: 10.1111/j.1398-9995.2009.02188.x
– ident: e_1_2_12_81_1
  doi: 10.1067/mjd.2000.104517
– ident: e_1_2_12_62_1
  doi: 10.1016/0140-6736(92)90666-Q
– ident: e_1_2_12_13_1
  doi: 10.1016/S0091-6749(81)90209-8
– volume-title: Review Manager (RevMan) [Computer program]. Version 5.3
  year: 2014
  ident: e_1_2_12_9_1
– ident: e_1_2_12_84_1
  doi: 10.1111/j.1398-9995.2009.02325.x
– ident: e_1_2_12_141_1
  doi: 10.1111/j.1398-9995.1980.tb01728.x
– volume: 75
  start-page: 484
  issue: 6
  year: 1995
  ident: e_1_2_12_73_1
  article-title: Pseudoallergen‐free diet in the treatment of chronic urticaria. A prospective study
  publication-title: Acta Derm Venereol
  doi: 10.2340/0001555575484487
– ident: e_1_2_12_18_1
  doi: 10.1111/bjd.13621
– ident: e_1_2_12_37_1
  doi: 10.2340/00015555-2941
– ident: e_1_2_12_95_1
  doi: 10.1111/bjd.14768
– ident: e_1_2_12_156_1
  doi: 10.1016/j.jaci.2014.08.025
– ident: e_1_2_12_127_1
  doi: 10.1111/j.1525-1470.2009.00869.x
– ident: e_1_2_12_137_1
  doi: 10.1155/2013/130905
– ident: e_1_2_12_47_1
  doi: 10.1111/jdv.12739
– ident: e_1_2_12_72_1
  doi: 10.1046/j.1365-2133.2000.03664.x
– ident: e_1_2_12_43_1
  doi: 10.1111/all.12209
– ident: e_1_2_12_117_1
  doi: 10.1001/jamadermatol.2013.8705
– ident: e_1_2_12_93_1
  doi: 10.1016/j.jaci.2008.12.008
– ident: e_1_2_12_160_1
  doi: 10.1016/j.jclinepi.2010.07.015
– ident: e_1_2_12_24_1
  doi: 10.1111/j.1398-9995.2010.02496.x
– ident: e_1_2_12_32_1
  doi: 10.1016/j.vhri.2016.07.008
– ident: e_1_2_12_113_1
  doi: 10.1111/all.12870
– ident: e_1_2_12_27_1
  doi: 10.1111/cea.12900
– ident: e_1_2_12_159_1
  doi: 10.18176/jiaci.0179
– ident: e_1_2_12_57_1
  doi: 10.1111/all.14037
– ident: e_1_2_12_147_1
  doi: 10.1111/pai.12555
– ident: e_1_2_12_80_1
  doi: 10.1111/jdv.13966
– volume: 39
  start-page: 237
  issue: 7
  year: 2007
  ident: e_1_2_12_134_1
  article-title: Low‐dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria
  publication-title: Eur Ann Allergy Clin Immunol
– ident: e_1_2_12_151_1
  doi: 10.1111/j.1399-3038.2004.00167.x
– ident: e_1_2_12_55_1
  doi: 10.1111/j.1399-3038.2010.01120.x
– ident: e_1_2_12_82_1
  doi: 10.1111/j.1398-9995.2008.01913.x
– start-page: 85
  volume-title: Proceedings of the international symposium on urticaria
  year: 1998
  ident: e_1_2_12_69_1
– ident: e_1_2_12_19_1
  doi: 10.1111/cea.12348
– volume: 3
  start-page: 23
  year: 1989
  ident: e_1_2_12_89_1
  article-title: Therapeutic effect of cetirizine 2 HCl in delayed pressure urticaria
  publication-title: Health Sci Rev
– ident: e_1_2_12_63_1
  doi: 10.1016/j.jaci.2015.06.021
– ident: e_1_2_12_130_1
  doi: 10.1111/cea.12944
– ident: e_1_2_12_16_1
  doi: 10.1097/00000372-198912000-00003
– ident: e_1_2_12_120_1
  doi: 10.1007/s12016-020-08794-6
– ident: e_1_2_12_102_1
  doi: 10.1016/j.jaci.2017.06.032
– ident: e_1_2_12_135_1
  doi: 10.1016/j.anai.2009.12.007
– ident: e_1_2_12_101_1
  doi: 10.1016/j.jaci.2015.12.1342
– ident: e_1_2_12_41_1
  doi: 10.1111/j.1398-9995.2008.01726.x
– ident: e_1_2_12_48_1
  doi: 10.1111/ced.12547
– ident: e_1_2_12_111_1
  doi: 10.1016/j.jaci.2017.01.042
– ident: e_1_2_12_38_1
  doi: 10.1111/all.14757
– ident: e_1_2_12_39_1
  doi: 10.1159/000507218
– ident: e_1_2_12_132_1
  doi: 10.1046/j.1365-2133.1998.02033.x
– ident: e_1_2_12_15_1
  doi: 10.1159/000023902
– ident: e_1_2_12_54_1
  doi: 10.4168/aair.2017.9.3.212
– ident: e_1_2_12_131_1
  doi: 10.1016/j.jaci.2006.12.658
– ident: e_1_2_12_5_1
  doi: 10.1111/all.12313
– ident: e_1_2_12_20_1
  doi: 10.1111/bjd.12991
– ident: e_1_2_12_116_1
  doi: 10.1016/j.jaci.2017.10.018
– ident: e_1_2_12_78_1
  doi: 10.1111/j.1365-2133.2004.06095.x
– volume: 88
  start-page: 247
  issue: 3
  year: 2008
  ident: e_1_2_12_140_1
  article-title: Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial
  publication-title: Acta Derm Venereol
  doi: 10.2340/00015555-0434
– ident: e_1_2_12_158_1
  doi: 10.1155/2015/368053
– ident: e_1_2_12_2_1
  doi: 10.1111/j.1398-9995.2009.02179.x
– ident: e_1_2_12_155_1
  doi: 10.2165/00002018-200831090-00006
– ident: e_1_2_12_17_1
  doi: 10.1111/j.1398-9995.2011.02570.x
– ident: e_1_2_12_119_1
– volume: 20
  start-page: 386
  issue: 5
  year: 2010
  ident: e_1_2_12_129_1
  article-title: Usefulness of a short course of oral prednisone in antihistamine‐resistant chronic urticaria: a retrospective analysis
  publication-title: J Invest Allerg Clin
– volume: 65
  start-page: 449
  issue: 5
  year: 1985
  ident: e_1_2_12_138_1
  article-title: Ultraviolet light therapy in chronic urticaria
  publication-title: Acta Derm Venereol
  doi: 10.2340/0001555565449450
– ident: e_1_2_12_107_1
  doi: 10.1016/j.jaci.2017.01.043
– ident: e_1_2_12_12_1
  doi: 10.1136/bmj.311.7001.376
– ident: e_1_2_12_59_1
  doi: 10.1111/j.0736-8046.2004.21202.x
– ident: e_1_2_12_85_1
  doi: 10.1111/j.1398-9995.2007.01620.x
– ident: e_1_2_12_152_1
  doi: 10.1159/000321181
– ident: e_1_2_12_104_1
  doi: 10.1111/bjd.19425
– ident: e_1_2_12_21_1
  doi: 10.1056/NEJM199506293322608
– ident: e_1_2_12_94_1
  doi: 10.1111/j.1468-3083.2009.03289.x
– ident: e_1_2_12_33_1
  doi: 10.1007/s40257-015-0134-8
– ident: e_1_2_12_66_1
  doi: 10.1007/978-3-642-85267-1_2
– volume: 19
  start-page: 1013
  issue: 7
  year: 2021
  ident: e_1_2_12_60_1
  article-title: Epidemiology of urticaria in German children
  publication-title: J Dtsch Dermatol Ges
  doi: 10.1111/ddg.14485
– ident: e_1_2_12_96_1
  doi: 10.1016/j.jaci.2011.06.010
– ident: e_1_2_12_34_1
  doi: 10.1007/s40273-016-0412-1
– ident: e_1_2_12_56_1
  doi: 10.1001/jamadermatol.2017.3183
– ident: e_1_2_12_77_1
  doi: 10.1111/j.1365-2222.2008.03110.x
– ident: e_1_2_12_22_1
  doi: 10.1056/NEJMcp011186
– volume: 57
  start-page: 369
  issue: 4
  year: 1977
  ident: e_1_2_12_142_1
  article-title: Tranexamic acid (Cyklokapron) in chronic urticaria: a double‐blind study
  publication-title: Acta Derm Venereol
  doi: 10.2340/0001555557369370
– ident: e_1_2_12_40_1
  doi: 10.1097/ACI.0000000000000163
– ident: e_1_2_12_92_1
  doi: 10.1016/j.jaci.2009.11.047
– ident: e_1_2_12_29_1
  doi: 10.1111/all.13209
– ident: e_1_2_12_121_1
  doi: 10.1111/bjd.16379
– ident: e_1_2_12_124_1
  doi: 10.1038/sj.bjp.0707002
– ident: e_1_2_12_103_1
  doi: 10.1159/000320233
– ident: e_1_2_12_149_1
  doi: 10.1111/j.1365-2125.2006.02810.x
– ident: e_1_2_12_30_1
  doi: 10.1046/j.1365-2133.1997.d01-1168.x
– ident: e_1_2_12_74_1
  doi: 10.1111/j.1365-2133.1981.tb15306.x
– ident: e_1_2_12_115_1
  doi: 10.1111/jdv.14075
– ident: e_1_2_12_3_1
  doi: 10.1111/j.1398-9995.2009.02178.x
– ident: e_1_2_12_97_1
  doi: 10.1016/j.jaci.2011.04.038
– ident: e_1_2_12_146_1
  doi: 10.1159/000292947
– ident: e_1_2_12_126_1
  doi: 10.1016/j.jaip.2017.07.017
– ident: e_1_2_12_6_1
– ident: e_1_2_12_31_1
  doi: 10.1034/j.1398-9995.2003.00091.x
– ident: e_1_2_12_53_1
  doi: 10.2500/aap.2016.37.4010
– volume: 75
  start-page: 484
  issue: 6
  year: 1995
  ident: e_1_2_12_68_1
  article-title: Pseudoallergen‐free diet in the treatment of chronic urticaria ‐ A prospective study
  publication-title: Acta Derm Venereol
  doi: 10.2340/0001555575484487
– ident: e_1_2_12_4_1
  doi: 10.1111/all.12313
– ident: e_1_2_12_50_1
  doi: 10.1016/j.jdermsci.2014.04.007
– ident: e_1_2_12_133_1
  doi: 10.1046/j.1365-2133.2003.05486.x
– volume-title: GRADEpro GDT: GRADEpro Guideline Development Tool
  year: 2015
  ident: e_1_2_12_11_1
– ident: e_1_2_12_36_1
  doi: 10.1111/all.13397
– ident: e_1_2_12_45_1
  doi: 10.1016/j.jaci.2013.12.1076
– ident: e_1_2_12_128_1
  doi: 10.2340/0001555576295297
– ident: e_1_2_12_88_1
  doi: 10.1159/000246281
– ident: e_1_2_12_99_1
  doi: 10.1056/NEJMoa1215372
– ident: e_1_2_12_8_1
  doi: 10.1111/all.13414
– volume: 8
  start-page: 6
  issue: 1
  year: 2015
  ident: e_1_2_12_65_1
  article-title: Helicobacter pylori and gastric cancer: a state of the art review
  publication-title: Gastroenerol Hepatol Bed Bench
– ident: e_1_2_12_148_1
  doi: 10.2500/aap.2017.38.4050
– ident: e_1_2_12_46_1
  doi: 10.1111/all.12884
– ident: e_1_2_12_90_1
  doi: 10.1016/0091-6749(71)90083-2
SSID ssj0007290
Score 2.7448716
Snippet This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of...
SourceID hal
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 734
SubjectTerms Allergies
Angioedema
Angioedema - diagnosis
Angioedema - etiology
Angioedema - therapy
Asthma
Chronic Disease
consensus
Dermatology
Edema
evidence‐based
hives
Humans
Immunology
itch
Life Sciences
mast cell
Medical diagnosis
Prevalence
Quality of Life
Urticaria
Urticaria - diagnosis
Urticaria - epidemiology
Urticaria - etiology
wheal
Title The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.15090
https://www.ncbi.nlm.nih.gov/pubmed/34536239
https://www.proquest.com/docview/2633103220
https://www.proquest.com/docview/2574399115
https://hal.science/hal-03982425
Volume 77
WOSCitedRecordID wos000708958300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Free Content
  customDbUrl:
  eissn: 1398-9995
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0007290
  issn: 0105-4538
  databaseCode: WIN
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
– providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1398-9995
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0007290
  issn: 0105-4538
  databaseCode: DRFUL
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELZKi1Av_FMWSmUQBw4Nm8TOj8UpanfbSmG1QlTsLfIvRFqyqNv0GXgeHoEnY8bJRq0ACYlLlMRjxbFn7O-bTMaEvM4xh5nUWRByqQIu0jgQDlhrrBhwIJ0DpvUp88tsNssXCzHfIu82_8J0-SEGhxtahp-v0cClWl8zcrlcvgU0I4Cv70QRy1ClYz4fpuGsd7AAgAg4mHWfVgjDeIaqNxajW18wFPJ3nHkTtvp1Z3rvv1p8n9zt4SYtOv14QLZs85Dced9_UH9EvoOa0Pq6V5BOiuLobHxS_PxRTmZj9NaftPUxTODjYl5gGf3cYm4sqE8B8VJAkNRYVzc--OuQasTjGIAku2vTBfPV60MqG0O_DvE2dOVoiw0Dui4fk_Pp5OPRadBvzhBoHgPlzFwWRjJVsQkTy4xJhDBpmMtccKWZMDKNrFFxbJWTihttlbImgXGwTqssMewJ2W5WjX1KqDBae2KXp5I7l4A4iywHYiScBEQyIm82o1TpPnM5bqCxrDYMBnq28j07Iq8G0W9duo4_CsFQD-WYYPu0KCu8FzKRIwm7gofubzSh6s16XcUpw33Z4P1H5OVQDAaJX1lkY1ctyCSe4wHSHpG9ToOGRzFQRMCbAt7IK8rf21gVZelPnv276HOyG-PPGT5Cbp9sX1609gW5ra8u6_XFgbcOOGaL_IDsHH-Ynpdw9els9gvS4xN2
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB6VgoALvwUWChjEgUPDZhPnxxKXqGy7FelqD0XqLfIvRFqyqNv0GXgeHoEnY8bJRq0ACYlbEo8Vx56xv288GQO8ySmHmdRZEHKpAi7SKBAOWWukYuRAOkdM61Pml9l8np-eisUWvN_8C9PlhxgcbmQZfr4mAyeH9CUrl8vlO4QzAgn7dY6rEgX0RXwxzMNZ72FBBBFwtOs-rxDF8QxVr6xG175QLOTvQPMqbvULz8Hd_2vyPbjTA05WdBpyH7Zs8wBuHvdb6g_hOyoKqy_7Bdm0KPaPxofFzx_ldD4mf_1hW3_AKXxcLAoqY59byo6F9RliXoYYkhnr6saHf-0xTYicQpBkd2-6cL56vcdkY9jXIeKGrRxrqWFI2OUOfDqYnuzPgv54hkDzCEln5rJwIlMVmTCxsTGJECYNc5kLrnQsjEwn1qgosspJxY22SlmT4EBYp1WWmPgRbDerxj4BJozWntrlqeTOJSgeTyxHaiScREwygrebYap0n7ucjtBYVhsOgz1b-Z4dwetB9FuXsOOPQjjWQzml2J4VZUXPwljkRMMu8KW7G1WoesNeV1Ea08ls-P0jeDUUo0nSPots7KpFmcSzPMTaI3jcqdDwqhg1ERGnwC_ymvL3NlZFWfqLp_8u-hJuzU6Oy6o8mn98Brcj-lXDx8vtwvb5WWufww19cV6vz154U_kFk10Tww
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VgqpeeFMWChjEgUPDZvO2xCVqd9sVIdoDiN4iPyHSkq26TX8Dv4efwC9jxslGrQAJiVsSjxU_Zuzvs8djgNcZxTATKvX8SEgv4kngcYusNZAhciCVIaZ1IfOLtCyz01O-2IJ3m7MwXXyIYcGNLMON12Tg5kzbK1Yulsu3CGc4EvabEeJwcuj6PC-HcTjtV1gQQXgR2nUfV4j8eIas12ajG1_JF_J3oHkdt7qJZ3bn_4p8F273gJPlnYbcgy3T3IedD_2W-gP4jorC6qvrgmya54fz8XH-80cxLce0Xn_c1kc4hI_zRU5p7EtL0bEwP0PMyxBDMm1s3Tj3rwOmCJGTC5Lo3nXnzlevD5hoNPs2eNywlWUtFQwJu3gIn2bTj4cnXn89g6eiAElnalN_IhIZaD82odYx5zrxM5HxSKqQa5FMjJZBYKQVMtLKSGl0jB1hrJJprMNHsN2sGvMYGNdKOWqXJSKyNkbxcGIipEbcCsQkI3iz6aZK9bHL6QqNZbXhMNiylWvZEbwaRM-6gB1_FMK-HtIpxPZJXlT0zQ95RjTsEn-6v1GFqjfsdRUkId3MhvUfwcshGU2S9llEY1YtysSO5SHWHsFep0LDr0LUREScHGvkNOXvZazyonAPT_5d9AXsLI5mVTEv3z-F3YBOajh3uX3YvjhvzTO4pS4v6vX5c2cpvwDGUBO0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+international+EAACI%2FGA%C2%B2LEN%2FEuroGuiDerm%2FAPAAACI+guideline+for+the+definition%2C+classification%2C+diagnosis%2C+and+management+of+urticaria&rft.jtitle=Allergy+%28Copenhagen%29&rft.au=Zuberbier%2C+Torsten&rft.au=Abdul+Latiff%2C+Amir+Hamzah&rft.au=Abuzakouk%2C+Mohamed&rft.au=Aquilina%2C+Susan&rft.date=2022-03-01&rft.pub=Wiley&rft.issn=0105-4538&rft.eissn=1398-9995&rft.volume=77&rft.issue=3&rft.spage=734&rft.epage=766&rft_id=info:doi/10.1111%2Fall.15090&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=oai%3AHAL%3Ahal-03982425v1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-4538&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-4538&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-4538&client=summon